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Abstract 
Metallo-β-lactamases (MBLs) are major contributors to bacterial antibiotic resistance due to their 
ability to cleave most β-lactam antibiotics.  At the present time there are no clinically approved 
inhibitors of MBLs.  However, previous preliminary studies have demonstrated that cationic 
peptides have the ability to inhibit these enzymes. 
Herein, more thorough investigations into the structure-activity relationship between two 
MBLs, VIM-2 and IMP-1, and cationic peptides are described, demonstrating that the inhibitory 
potency of these peptides increased with the number of arginine residues (IC50 of 10 nM for the 
most potent VIM-2 inhibitor).  The degree of inhibition also varied depending on the β-lactam 
substrate and the MBL employed.  Furthermore, steady-state and stopped-flow 
spectrophotometric studies demonstrated that the inhibition mediated by these peptides followed 
a complex mode of inhibition.  In addition, results from spectroscopic studies (including UV-Vis, 
tryptophan fluorescence and dynamic light scattering) showed that the inhibition of MBLs by 
cationic peptides results in partially reversible peptide-influenced MBL aggregation.  The better 
understanding of the relationship between these peptides and MBLs may lead to the development 
of novel MBL inhibitors suitable for clinical use. 
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Chapter 1: Introduction 
1.1 Microorganisms  
Microorganisms are found everywhere in the environment from air, water, soil and the human 
body [1].  Most microorganisms are beneficial, and can promote human health and well-being.  
These microorganisms are commonly included in various types of food products such as milks, 
cheeses and yogurts.  They encourage the maintenance of a healthy intestinal microbial flora, 
thereby providing protection against gastrointestinal disorders such as inflammatory bowel 
disease and colon cancer [2, 3].  The large intestine in the human body is estimated to contain 
hundreds of different types of bacterial species averaging around 1012 bacteria per gram of 
intestine [2].  Although numerous microorganisms confer many health benefits for the human 
population, some microorganisms are pathogenic and can cause serious health concerns.  
Bacterial infections such as meningitis, pneumonia, tetanus and tuberculosis are the most 
common infectious diseases worldwide causing a high degree of mortality among the human 
population [4].   
1.2 Discovery of Microorganisms and Vaccination  
Throughout history, disease-causing bacteria wreaked havoc around the globe as the human 
population went unaware of their existence due to their small size.  Sadly, this did not prevent 
these microorganisms from causing numerous epidemics around the world such as the Black 
Death (bubonic plague) which claimed the lives of millions of people in Europe after 1346.  This 
plague was caused by the Gram-negative bacterium Yersinia pestis [5, 6].  The awareness of the 
existence of microorganisms began in 1683 with the innovative microscopy of Anthony Van 
Leeuwenhoek.  Among the animalcules from his teeth, Van Leeuwenhoek first observed 
bacterial species [5, 7].  However, it would take almost another two centuries for this discovery 
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to promote any advancement in the detection of some of the most deadly microbes since the 
existence of these small organisms was regarded as an interesting, yet irrelevant fact.  
Regardless, the awareness of the existence of these microorganisms would go on to create a 
pathway for the discovery of preventative measures to combat these pathogenic bacteria and 
viruses [7]. 
1.2.1 Edward Jenner and the Smallpox Vaccine  
The human population’s battle against pathogenic bacteria and viruses would be transformed by 
the fight against smallpox.  Smallpox was a highly virulent, easily transmittable infectious 
disease caused by two virus variants known as Variola major and Variola minor [8].  In 18th 
century Europe, an estimated 400,000 people died each year of smallpox, and those who 
survived were usually left severely disfigured due to scars.  In addition, one third of the smallpox 
survivors were often left blind due to corneal infections [9].  Interestingly, it was also observed 
that the survivors of smallpox became immune to the disease.  Henceforth, variolation became 
the first method used to combat this highly contagious and deadly disease.  The variolation 
protection method was introduced in Europe in 1717 by Lady Mary Wortley Montague.  The 
technique involved taking a small amount of smallpox pus, and scratching it into the arms of 
healthy people.  Variolation was intended to produce a more mild form of the disease, but the 
disease still proved to be fatal in 2% to 3% of variolated people [9, 10].  Furthermore, since 
smallpox, no matter how mild, was still highly contagious, the variolated individuals were still 
fully capable of transmitting smallpox to other people, and were often the cause of new 
outbreaks of the disease [11, 12].  Nevertheless, mortality rates associated with the variolation 
technique were still 10 times lower than those associated with naturally occurring smallpox 
which demonstrated a mortality rate of 30% [10, 12].   
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In 1757, an 8-year-old boy by the name of Edward Jenner living in England was variolated 
against smallpox [12].  As he grew older, Jenner developed a strong interest in the knowledge 
that milkmaids who contracted cowpox did not develop smallpox [9, 10].  Jenner concluded that 
cowpox could be transmitted from one person to another to protect against smallpox [9].  In May 
1796, Jenner inoculated his gardener’s 8-year-old son, James Phipps, with cowpox obtained from 
the lesions of a local milkmaid.  Afterwards, in July 1796, Jenner inoculated Phipps again, but 
with smallpox.  Fortunately, Phipps demonstrated immunity to smallpox since no smallpox 
infection occurred, and Jenner concluded that the vaccination was a success.  This was the first 
ever successful vaccination.  In 1798, Jenner published his research and received great 
opposition from the medical community.  However, Jenner was not discouraged by the 
opposition and continued to distribute his smallpox vaccine.  By the summer of 1799, numerous 
members of the medical community had confirmed Jenner’s hypothesis as over 1,000 people had 
been vaccinated against smallpox from Europe to North America to Asia [11].  Therefore, in 
1840 in England, variolation was made illegal while vaccination was rendered free upon request 
[10].  However, vaccination also demonstrated some drawbacks.  It was discovered that 
vaccination did not confer a lifelong immunity against the disease, and subsequent vaccination 
was necessary to ensure protection against smallpox.  The main drawbacks of Jenner’s 
vaccination presented themselves when it came to ensuring the quantity and the quality of the 
vaccine.  Several diseases contracted by cattle resembled cowpox, although they were caused by 
different viruses.  Furthermore, contamination with other microorganisms was also common 
resulting in vaccinated people developing hepatitis B and syphilis.  In addition, the vaccine was 
susceptible to deactivation by heat during its transportation.  This would persist until the 1930s 
when refrigeration became widely available [11].  By the 1950s, smallpox was eradicated in 
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many regions of Europe and North America.  In 1958, the process of the worldwide eradication 
of smallpox began since the disease was still demonstrating devastating effects in 63 countries.  
On May 8th, 1980, close to two hundred years after the first vaccination by Jenner, the World 
Health Organization finally announced the worldwide eradication of smallpox [9]. 
1.2.2 Robert Koch 
Although vaccination was common after Jenner’s discovery, the underlining cause of infectious 
diseases remained unknown.  German physician Robert Koch was the first to actually establish 
the link between a bacterium and the causative agent of an infectious disease [13].  Anthrax is a 
highly virulent, highly contagious, potentially fatal infectious disease.  This disease not only 
affects the human population, but also wreaks devastation on animals such as cattle, sheep and 
horses since it has the capacity to be transmitted to all warm-blooded animals [14].  In 1870, the 
disease killed 56,000 farm animals and 528 people in Russia [13].  Koch’s studies demonstrated 
that rod-shaped structures were present in the blood of anthrax-infected animals.  In addition, the 
blood of these disease-stricken animals could transmit anthrax to healthy animals through 
inoculation [13, 14].  As Koch observed these rod-shaped structures through a microscope, he 
concluded that they were actually living bacteria [13, 15].  Koch later identified these bacteria as 
the Gram-positive bacterium Bacillus anthracis which was originally discovered in 1850 by 
French physician Casimir Davaine and German physician Aloys Pollender [15].  In 1876, Koch 
concluded that B. anthracis was the cause of anthrax, and that the presence of these bacteria was 
required for the transmission of anthrax among animals [13, 15].   
Following his research on anthrax, Koch decided to study tuberculosis.  Tuberculosis (also 
known as TB, which is short for tubercle bacillus) is one of the oldest and deadliest infectious 
diseases.  TB typically attacks the lungs, and is transmitted through the respiratory route (i.e., 
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coughs and sneezes) [16, 17].  TB dates back to over 10,000 years ago, and continues to be fatal 
for approximately two million people each year [17–19].  Although tuberculosis existed for 
thousands of years, the bacillus causing the disease, Mycobacterium tuberculosis, was originally 
identified and described by Koch in 1882 [17, 20].   
Following his work with tuberculosis, Koch focused his attention on cholera.  Cholera is an 
infectious disease which is characterized by voluminous amounts of watery diarrhea that results 
in high mortality rates despite rehydration therapy [21, 22].  Cholera pandemics have been 
recorded since 1817 [22, 23].  In 1884, Koch identified that Gram-negative, comma-shaped 
bacilli were responsible for causing cholera.  These bacilli, known as Vibrio cholerae, were 
originally discovered by Italian anatomist Filippo Pacini in 1854 [21, 24].  Although, Robert 
Koch discovered the etiologic agents for three different infectious diseases, his identification of 
the tuberculosis bacteria still remains his greatest scientific achievement over 100 years later [18, 
25].    
1.2.3 Louis Pasteur 
Louis Pasteur, also known as the father of microbiology, played an essential role in the history of 
microorganisms and vaccination.  In 1879, Pasteur successfully isolated the chicken cholera 
bacillus, and demonstrated that the disease could be transmitted to healthy chicken through the 
injection of this bacillus.  However, his research was interrupted, and a culture containing the 
bacilli involved in chicken cholera aged in the laboratory.  This culture later failed to induce 
cholera when injected into healthy chickens upon Pasteur’s return.  In addition, Pasteur observed 
resistance to cholera in these healthy chickens even when he tried re-injecting them with a fresh 
culture of the cholera bacillus [26, 27].   Pasteur understood that the chickens survived since the 
cholera-causing bacillus was attenuated (i.e., weakened) due to their exposure to air.  Pasteur 
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observed a connection between his observations and that of Edward Jenner’s research on 
vaccination, and therefore named his injections vaccines in honour of Jenner’s discovery.  
Henceforth, Pasteur suggested that an animal could become less susceptible to a bacterial disease 
as they come into contact with an attenuated form of the etiologic bacteria [26, 28].   
In the 1870s, Pasteur studied sheep anthrax since this disease was causing a lot of devastation 
on livestock.  Pasteur was already aware of Robert Koch’s discovery that Bacillus anthracis was 
the etiological agent of anthrax [26, 27].  Pasteur had a harder time creating a vaccine for anthrax 
since the bacillus could be present in its rod form (i.e., sensitive to attenuation) and its spore 
form (i.e., resistant to attenuation).  Pasteur had to find a way to keep the bacteria alive while 
preventing spore formation.  Pasteur finally attenuated the bacteria by storing them in 
oxygenated containers at 42°C to 43°C [26].  In 1881, Pasteur injected a variety of animals with 
anthrax bacilli.  Some of the animals had been vaccinated with Pasteur’s attenuated anthrax 
bacilli while others remained unvaccinated.  The experiment was considered completely 
successful as only the vaccinated animals survived [14, 26].   
Following his work of anthrax, Pasteur went on to study and work on rabies.  Rabies is an 
infectious disease affecting all warm-blooded animals.  Although rabies is mostly prevalent 
among wild animals such as the fox and the dog, it can also be transmitted to humans through 
exposure to saliva from these rabid animals [29, 30].  This disease dates back to ancient Egypt, 
and is caused by a virus belonging to the Lyssavirus genus [30].  Rabies causes acute 
inflammation of the brain through the infection of the central nervous system.  On average, one 
person every 15 min dies from rabies while 300 other people are exposed [31].  The rabies 
vaccine was initially created by a French doctor and a colleague of Pasteur, Émile Roux, who 
had been working on killing the virus by drying out the spinal cords of rabbits that were infected 
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with the disease.  Pasteur sped up the dehydration process of the spinal cords through the 
addition of potassium particles [26].  The vaccine was initially tested on 9-year-old Joseph 
Meister in 1885 after the boy was badly mauled by a rabid dog, and his death appeared inevitable 
[5, 26].  Although Pasteur’s vaccines were not as successful as Jenner’s smallpox vaccine (i.e., 
the smallpox vaccine is still described as the most successful vaccine in history), Pasteur still 
made significant contributions to the world of microbiology through his effective vaccines 
created by the attenuation of microorganisms [10, 26].  However, although vaccinations were a 
great advancement for preventing infectious diseases, there was still a need to create something 
that could ultimately combat the bacteria causing these diseases once someone was already 
infected.         
1.3 History of Antibiotics 
In 1942, the term antibiotic was used for the first time by Selman Waksman.  This term was 
originally used to describe small molecules synthesized by microorganisms that hindered the 
growth of other microorganisms [32].  The first antibiotic discovered was the sulfa drug 
arsphenamine (initially known as compound 606 or Salvarsan).  This antibiotic was originally 
discovered in 1909 by Paul Ehrlich and Sahachiro Hata, and was used for the treatment of 
syphilis [33].  In 1932, another sulfa drug was synthesized by two German chemists, Josef Klarer 
and Fritz Mietzsch.  This sulfa drug, Prontosil, whose antimicrobial properties were discovered 
by German physician Gerhard Domagk, was the first to be commercially available [33, 34].  This 
breakthrough in the fight against bacterial infections resulted in a mass production of natural and 
synthetic antibiotics from 1945 to 1955 [32].   
Penicillin, an antibiotic derived by the Penicillium fungi, was the first antibiotic that 
demonstrated significant results in combating bacterial infections that were previously fatal for 
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humans [4, 32, 35].  Penicillin was originally discovered by French medical student Ernest 
Duchesne.  In 1897, Duchesne demonstrated that the fungus Penicillium glaucum had the ability 
to combat infections caused by Escherichia coli and Salmonella typhi [36].  However, Duchesne 
never continued his research, and the discovery of penicillin was credited to Scottish 
bacteriologist Alexander Fleming [36, 37].  In 1928, Fleming accidently discovered the anti-
pathogenic properties of mold upon returning from his vacation.  Fleming noticed that mold was 
growing on some discarded Petri dishes containing staphylococci.  Upon further observation, 
Fleming discovered that no staphylococci were growing around the mold.  Fleming concluded 
that the mold released a substance with antibacterial properties.  This substance was later termed 
penicillin.  Fleming published his findings in 1929, but stopped studying penicillin in 1931 as he 
was never able to concentrate or purify the antibiotic.  The commercialization of penicillin would 
begin in 1940 with the successful production and purification of penicillin by Australian 
pathologist Howard Florey and German-born British biochemist Ernst Chain [37].  With the 
discovery of these antibiotics, the so-called miracle drugs, it was believed that the fight against 
infectious diseases had been won [38].     
1.4 Antibiotics 
Antibiotics are chemical substances that either restrain the growth (bacteriostatic agent) or kill 
the bacteria (bactericidal agent) causing bacterial infections.  However, the mechanism of action 
of antibiotics is rarely exclusively bactericidal or bacteriostatic [39, 40].  Even antibiotics 
categorized under bactericidal usually fail to kill every bacterium causing the infectious disease.  
In addition, certain bacteriostatic antibiotics can kill 90% to 99% of the bacteria causing the 
infection, but cannot be considered bactericidal as over 1% of bacteria remain [39].  
Furthermore, antibiotics can also be classified depending on the range of bacteria that they affect.  
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Broad-spectrum antibiotics are effective against a wide range of microorganisms including both 
Gram-positive and Gram-negative bacteria.  However, these antibiotics not only target the 
pathogenic bacteria causing the bacterial infections, but also affect the bacteria residing in the 
natural intestinal flora of the host.  In contrast, narrow-spectrum antibiotics are only active 
against a narrow range of bacteria, either Gram-positive or Gram-negative.  These antibiotics 
only target the pathogenic bacterial strains causing the bacterial infection, and do not majorly 
affect the natural intestinal flora of the host [41, 42].  Furthermore, antibiotics can be produced 
either synthetically or by microorganisms.  Therefore, antibiotics are either classified as natural, 
semi-synthetic or synthetic agents.  Natural antibiotics are produced solely by microorganisms.  
Many of these antibiotics were obtained through secretions by fungi or soil bacteria.  Semi-
synthetic antibiotics are synthesized through chemical modifications of natural compounds.  
These chemical modifications are typically performed to improve the efficacy of the natural 
antibiotic or to reduce side effects associated with its use.  Synthetic antibiotics are produced 
exclusively in the laboratory [43].  Therefore, antibiotics are typically classified, based on their 
mechanism of action (i.e., bacteriostatic or bactericidal), their chemical structure, or their 
spectrum of activity.  However, antibiotics can also be grouped depending on their bacterial 
targets [4, 40].  
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Figure 1.1: Targets of antibiotics.  Most antibiotics target only three pathways: the ribosome 
(30S or 50S subunits), cells wall synthesis, and DNA replication (i.e., DNA gyrase or DNA-
directed RNA polymerase).  Figure taken, with permission, from reference [44] and Macmillan 
Publishers Ltd.  © 2013 Macmillan Publishers Ltd.  All rights reserved. 
Antibiotics are effective at slowing down or killing bacteria since they have the capacity to 
inhibit essential components of microbial processes such as cell wall synthesis, DNA replication 
and protein synthesis.  Antibiotics are separated into several groups depending on the bacterial 
process that they inhibit [4, 40].  Quinolones are synthetic broad-spectrum antibiotics that inhibit 
DNA synthesis.  More specifically, quinolones inhibit DNA gyrase preventing bacterial DNA 
from unwinding and consequently, duplicating (see Figure 1.1).  The majority of clinically 
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relevant quinolones are fluoroquinolones (i.e., quinolones that contain a fluorine atom) [40, 45].  
The first quinolone discovered in 1962 was nalidixic acid, which was used for the treatment of 
urinary tract infections [45].  Rifamycins are natural and semi-synthetic bactericidal antibiotics 
that inhibit RNA synthesis through binding of prokaryotic DNA-directed RNA polymerase (see 
Figure 1.1) [40, 46].  The first rifamycin, rifampicin, was originally isolated from the Gram-
positive bacterium Amycolatopsis mediterranei (originally known as Streptomyces mediterranei) 
in 1957 [44, 46]. Antibiotics that inhibit bacterial protein synthesis are among the broadest 
classes of antibiotics, and they are divided into two subclasses depending on whether they inhibit 
the 30S or the 50S ribosomal subunit [40, 47].  In addition, protein synthesis also involves 
transfer RNA (tRNA) molecules that bring the amino acid moieties to the ribosome.  The 
ribosome has three tRNA binding sites: the A (aminoacyl) site, the P (peptidyl) site and the E 
(exit) site [47].  The 50S subunit inhibitors include macrolides, chloramphenicol, lincosamides 
and oxazolidinones (see Figure 1.1).  These antibiotics function by blocking the initiation of 
protein translation or by blocking the translocation of tRNAs located in the peptidyl site of the 
ribosome.  Blocking the translocation of peptidyl tRNAs inhibits the reaction that allows for the 
elongation of the nascent peptide chain.  The 30S inhibitors include tetracyclines and 
aminoglycosides.  Tetracyclines block tRNAs from assessing the aminoacyl site of the ribosome 
[40].  Aminoglycosides bind the 30S ribosomal subunit which interferes with the elongation of 
the nascent peptide chain.  This binding impairs the translational proofreading process resulting 
in misreading of the messenger RNA and/or premature termination [48].  Glycopeptides (e.g., 
vancomycin) and β-lactams (e.g., penicillins, cephalosporins, carbapenems and monobactams) 
are natural and semi-synthetic bactericidal antibiotics that inhibit cell wall synthesis (see Figure 
1.1).  Glycopeptides are narrow-spectrum antibiotics that inhibit cell wall synthesis by binding 
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the D-Ala-D-Ala terminus of the peptidoglycan subunits.  This binding inhibits the cross-linking 
of the peptidoglycan subunits by the penicillin-binding proteins (PBPs) [40, 44, 49].  β-Lactam 
antibiotics, such as benzylpenicillin, are broad-spectrum antibiotics that prevent the cross-linking 
of the peptidoglycan layer of the cell wall by inhibiting the PBPs themselves [40, 50, 51].  The β-
lactam antibiotics were the first antibiotics to demonstrate significant results in combating 
bacterial infections.  To date, they still remain the most commonly prescribed antibiotics for the 
treatment of bacterial infections [4, 32, 35, 52].          
1.5 β-Lactam  Antibiotics 
The β-lactam antibiotics are a broad class of antibiotics that includes all antibacterial agents 
containing a β-lactam ring (a four-membered cyclic amide) in their molecular structure [50, 52].  
The different subclasses of β-lactam antibiotics derive from modifications of the β-lactam 
nucleus and side chain(s).  The β-lactam nucleus is typically a bicyclic structure containing the 
β-lactam ring fused to a second ring structure [52].  As shown in Figure 1.2, there are six major 
subclasses of β-lactam antibiotics: the cephalosporins (cephems), the carbacephems, the penillins 
(penams), the clavams, the carbapenems and the monobactams.   
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Figure 1.2: Structures of the different types of β-lactam antibiotics.  The β-lactam nucleus is 
highlighted in red.  The six major subclasses of β-lactam antibiotics are shown in parentheses.  
Figure adapted from reference [53]. 
Cephalosporins, such as cephalothin, are β-lactam antibiotics that contain a β-lactam ring 
fused to a 6-membered thiazine ring with a sulfur atom (see Figure 1.2).  The 6-membered ring 
of cephalosporins is unsatured [54].  Carbacephams, such as loracarbef, are composed of a β-
lactam ring fused to an unsaturated 6-membered pyridine ring (see Figure 1.2).  The 6-membered 
ring of carbacephems, unlike that of cephalosporins, contains no heteroatom other than the 
nitrogen atom [55].  Penicillins, such as benzylpenicillin, are β-lactam antibiotics that contain a 
β-lactam ring fused to a 5-membered thiazolidine ring.  The 5-membered ring of penicillins is 
fully saturated [54].  Clavams, such as clavulanic acid, are β-lactamase inhibitors incorporating a 
β-lactam ring fused to a saturated 5-membered oxazolidine ring (see Figure 1.2) [56].  
Carbapenems, such as imipenem, are β-lactam antibiotics containing a saturated 5-membered 
pyrrolidine ring.  The pyrrolidine ring of carbapenems, unlike the thiazolidine ring of penicillins, 
contains no heteroatom other than the nitrogen atom [57].  Monobactams, such as aztreonam, in 
Cephalothin 
(Cephem – Cephalosporin)
Loracarbef
(Carbacephem)
Imipenem
(Carbapenem)
Benzylpenicillin
(Penam - Penicillin)
Clavulanic acid
(Clavam)
Aztreonam
(Monobactam)
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contrast to other subclasses of β-lactam antibiotics, contain only a single β-lactam ring (see 
Figure 1.2) [58].    
The most employed β-lactam antibiotics for the treatment of bacterial infections are the 
penams (penicillins) whose nucleus arises from the “fusion” of two amino acids, namely cysteine 
and valine (see Figure 1.3) [52, 54, 59].  The different side chains (R) attached to these rings 
determines the antibacterial characteristics of the penicillin antibiotics [52].       
 
Figure 1.3: Core structure of penicillins.  The β-lactam nucleus of penicillins results from the 
“fusion” of cysteine (blue) and valine (red). 
1.6 β-Lactam Antibiotics and Cell Wall Synthesis 
The cell wall is critical to bacterial cells as it is the main stress-bearing and shape-maintaining 
element [60].  Therefore, due to its critical role in bacterial survival, the cell wall and its enzymes 
are important targets for many antibiotics including β-lactams [61].  More specifically, β-lactam 
antibiotics inhibit the final stage of bacterial cell wall synthesis by preventing the cross-linking 
of the subunits forming the peptidoglycan layer of the cell wall.  This stage of cell wall synthesis 
is important since peptidoglycan is a polymer whose cross-linking allows the formation of a 
strong and elastic structure.  This allows the bacterium to maintain the structural integrity of its 
cell wall, and to uphold osmotic stability within its environment [60, 62].  
The basic structure of peptidoglycan is formed by alternating β-1,4-linked N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) subunits (see Figure 1.4) [60, 61].  
A specific pentapeptide is also attached to the D-lactyl moiety of each NAM subunit to allow 
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cross-liking to another strand of alternating NAM and NAG subunits.  This allows for the 
production of a three-dimensional mesh-like structure, and also causes NAM to terminate with 
two D-alanine residues [61].  The cross-linking of the pentapeptides of different strands of the 
peptidoglycan layer is mediated by transpeptidases known as penicillin-binding proteins (PBPs) 
[62].  PBPs assist in the cross-linking of two peptidoglycan strands through the removal of the C-
terminal D-Ala residue from one of the pentapeptides [63]. 
 
Figure 1.4: Structure of peptidoglycan from the bacterium Helicobacter pylori.  Peptidoglycan is 
composed on alternating β-1,4-linked N-acetylglucosamine (NAG) and N-acetylmuramic acid 
(NAM) subunits.  A pentapeptide is also attached to the NAM subunit for cross-linking of the 
peptidoglycan layers.  In H. pylori, the pentapeptide contains a meso-diaminopimelate (mDAP) 
residue.  The amino acids involved in cross-linking are indicated with arrows.  Figure modified 
from reference [64].  
β-Lactam antibiotics prevent peptidoglycan cross-linking since they are analogues of the D-
Ala-D-Ala sequence motif of the pentapeptide terminus of the NAM subunits [50, 51].  The 
structural similarity between the amino acid sequence found in the β-lactam antibiotics and the 
NAM pentapeptide terminus allows the antibiotics to irreversibly bind the PBPs.  Through this 
irreversible binding to the β-lactam antibiotics, the PBPs are inactivated and consequently, can 
no longer mediate the cross-linking of the peptidoglycan strands.  Therefore, the β-lactam 
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antibiotics obstruct the final stage of bacterial cell wall synthesis, and cause a diminished 
integrity of the cell wall [51].  A bacterium unable to maintain the integrity of its cell wall can no 
longer maintain structural integrity or osmotic stability.  Therefore, exposure to β-lactam 
antibiotics will eventually result in the lysis and the death of the bacterial cell [50].  However, 
with the commercial (over) usage of β-lactams and other antibiotics in the treatment of bacterial 
infections, the unavoidable problem of antibiotic resistance emerged [35]. 
1.7 Bacterial Antibiotic Resistance 
The first warning of the potential threat of antibiotic resistance came from Alexander Fleming 
who warned that the misuse of penicillin and other antibacterial agents could cause the selection 
of mutant forms of bacterial strains, especially in the case of widespread bacteria such as 
Staphylococcus aureus.  However, in the past, antibiotics were seen as miracle drugs and 
Fleming's warning was ignored [65].  These “miracle” drugs were then used as the treatment for 
the most minor infections as well as for infections that were non-bacterial in nature [38, 65].  As 
a result of this misuse, it did not take long to discover the truth behind Fleming's words.  For 
example, S. aureus became resistant to antibiotics at record breaking speeds.  Within a few years 
of the usage of penicillin in clinics, this antibiotic became ineffective against 50 % of S. aureus 
strains [65].  Therefore, due the misuse of antibiotics, today’s society is in the middle of an 
emerging antibiotic resistance crisis because of the ever increasing difficulty in treating bacterial 
infections with traditional antibiotics [4, 35]. 
1.7.1 Misuse of Antibiotics in Human Medicine 
With the discovery of antibiotics, it was believed that the fight against infections had been won.  
However, since the development of the first antibiotics, bacterial antibiotic resistance has been a 
threat in combating bacterial infections.  The emergence of bacterial resistance to antibiotics has 
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been aided by the misuse of these miracle drugs.  Major causes of antibiotic resistance include 
inappropriate prescription of antibiotics for flu, colds, coughs, sore throats and runny noses, 
which are caused by viruses [38].  Furthermore, many people shorten their antibiotic treatment 
course when symptoms subside, often resulting in re-infection since the shortened treatment only 
eradicated the most susceptible bacteria, and allowed the most dangerous ones to survive [66].  
In addition, poor hand hygiene by healthcare workers has also been associated with bacterial 
antibiotic resistance due to cross-contaminations of multiple patients by resistant microorganisms 
[67].  Therefore, the misuse of antibiotics by the human population continues to be an important 
factor in the emergence of antibiotic resistance. 
1.7.2 Transfer of Antibiotic Resistance Genes 
Despite the misuse of antibiotics, the selection of resistant bacteria due to improperly employed 
antibiotics is not the sole cause of the emergence of bacterial antibiotic resistance [68].  In 
bacteria, antibiotic resistance is mainly caused by the convergence of two main elements.  The 
first element is the presence of an antibiotic with the capacity of killing or inhibiting the growth 
of the majority of a bacterial colony.  The second element is the presence of at least one 
bacterium within that colony which can express the genes for antibiotic resistance.  The 
consequence of the combination of these two elements is that, upon the usage of an antibiotic, 
susceptible bacteria will die while resistant bacteria will survive.  This causes the selection of 
resistant bacteria which, consequently, causes the selection of the resistance genes which can 
then be transferred from one bacterium to another [65, 69].  These resistance genes are typically 
found in three primary bacterial mobile genetic elements: gene cassettes, transposons and 
plasmids.  These elements can carry the resistance genes for several antibiotics, and they have a 
very broad host range (i.e., they can be transferred to many different bacterial strains) [70].  Gene 
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cassettes typically contain a recombination site, and often carry genes for antibiotic resistance 
[70, 71].  Transposons (also known as transposable elements) are DNA sequences capable of 
changing positions within the genome through a process known as transposition.  Transposons 
also have the ability to move from one bacterial host to another.  Transposons often harbour 
antibiotic resistance genes.  Plasmids are small circular DNA molecules that are separate from 
chromosomal DNA, and can also replicate independently of the chromosome.  Plasmids often 
carry genes, such as antibiotic resistance genes, which are useful for the survival of their 
bacterial host [65, 70, 72, 73].  Therefore, the resistance genes located on these bacterial mobile 
elements are commonly transferred through three primary mechanisms: conjugation, 
transformation and transduction [65].      
 
Figure 1.5: Transfer mechanisms of bacterial antibiotic resistance genes.  DNA from the donor 
containing antibiotic resistance genes (pink) can be transferred between bacterial strains by three 
methods: conjugation, transformation and transduction.  Conjugation, transformation and 
transduction mediate the gene transfer through bacterial cell-to-cell contact, the uptake of free 
extracellular DNA and bacteriophages, respectively.  Figure modified from reference [74]. 
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Conjugation is the most common method for transferring antibiotic resistance genes among 
bacteria.  Conjugation involves the unidirectional transfer of genetic material from a donor to a 
recipient bacterial cell through direct cell contact (see Figure 1.5).  The contact is usually 
mediated by a conjugative pilus on the donor cell which allows for the temporary transfer of 
bacterial mobile genetic elements such as plasmids [65, 73].  Another method of resistance gene 
transfer is transformation.  Transformation involves the direct passage of exogenous DNA (also 
known as free DNA) containing resistance genes from one bacterial cell to another (see Figure 
1.5).  This free DNA usually originates from resistant bacteria that have died and broken apart in 
the extracellular environment.  The recipient bacteria can simply uptake the exogenous DNA into 
their cytoplasm and then incorporate this DNA into their own.  However, the incorporation of 
DNA from the extracellular milieu is a complex task requiring the bacteria to be in a state of 
competence for the transformation.  Competence describes the ability of a bacterial cell to uptake 
DNA from its extracellular environment [65, 75].  Over 40 bacterial species have been identified 
as being naturally competent and consequently, naturally transformable [75].  The last gene 
transfer method is known as transduction.  Transduction relies on the use of a vector such as a 
bacteriophage for the transfer (see Figure 1.5).  A bacteriophage (or phage) is a virus that can 
infect bacteria.  Therefore, the phage acquires the resistance genes from a previously infected 
bacterium, and introduces them into the receiving bacterium [65].   
1.8 Mechanisms of Bacterial Antibiotic Resistance 
Over the years, bacteria themselves have acquired the ability to counteract the effects of 
antibiotics through four primary mechanisms: altered antibiotic targets, altered outer membrane 
permeability, efflux pumps and β-lactamases. 
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1.8.1 Altered Antibiotic Targets 
The bacterial cell wall is an essential structure that provides support and protection to bacteria 
making it the target for many antibiotics including the β-lactam antibiotics [60, 61].  In the case 
of β-lactam antibiotics, their bacterial targets are the penicillin-binding proteins (PBPs) involved 
in the cross-linking of the peptidoglycan layer in the final stage of cell wall synthesis.  Therefore, 
resistance to β-lactam antibiotics can emerge though alterations of the PBPs.  These 
modifications result in reduced binding of the β-lactam antibiotics to these transpeptidases [76].  
This mechanism of resistance is prevalent in Gram-positive bacteria such as Staphylococcus 
aureus and Streptococcus pneumoniae, but is much less commonly used by Gram-negative 
bacteria.  Alterations in the PBPs can occur through mutations of the bacterial chromosomal 
genes encoding the PBPs or through the acquisition of foreign genes encoding new PBPs [76, 
77].  
Pneumococci are normally extremely sensitive to β-lactam antibiotics such as penicillin.  
Non-resistant pneumococci can be killed with concentrations of penicillin ≥ 0.1 µg/mL.  
Resistant strains of pneumococci have the ability to survive up to 8 µg/mL of penicillin [78].  β-
Lactam resistance in pneumococci is mainly the result of alterations in the PBPs.  Even a single 
amino acid substitution within the transpeptidase domain of the PBPs can allow for very low-
level resistance to penicillin [78].  Mutations occurring in the penicillin-binding motifs of the 
PBPs result in an increased resistance to penicillin in bacteria such as S. pneumonia.  These PBPs 
with decreased affinity for β-lactam antibiotics are known as low-affinity PBPs [78–80].  These 
low-affinity PBPs can be encoded by the mecA gene.  The mecA gene is found in numerous 
bacterial strains, but is most commonly found in S. aureus strains demonstrating resistance to 
methicillin [78].  Although the origins of acquisition of the mecA gene by S. aureus remains 
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unknown, it is believed that this bacterial strain acquired this gene through gene transfer from an 
unknown species [79].  The mecA gene encodes a low-affinity PBP known as PBP2a (penicillin-
binding protein 2a) which does not bind β-lactam antibiotics.  This enables the transpeptidase 
activity of the PBPs even in the presence of β-lactam antibiotics, preventing them from inhibiting 
bacterial cell wall synthesis [81].   
1.8.2 Altered Outer Membrane Permeability 
Gram-negative bacteria are generally more resistant to antibiotics than Gram-positive bacteria 
due to the presence of an outer membrane.  The outer membrane is an efficient barrier against 
certain antibiotics as it contains narrow porin channels which limit the penetration of hydrophilic 
solutes.  Alterations of these porins can limit the number of antibiotics that can cross the outer 
membrane, and penetrate into the bacterial cell [76, 82, 83].  For example, the Gram-negative 
bacterium Pseudomonas aeruginosa is resistant to imipenem due to the loss of a carbapenem-
specific porin [76].  In addition, the outer membrane contains a lipopolysaccharide leaflet which 
slows down the inward diffusion of solutes such as antibiotics [82, 83].  Therefore, antibiotic 
resistance in Gram-negative bacteria can be accomplished through the alteration of permeability 
of the outer membrane.  However, even in bacteria such as P. aeruginosa, containing an outer 
membrane of extremely low permeability, the periplasmic concentrations of many antibiotics 
reach 50% of their external concentrations in 10 s to 20 s [82].  This suggests that the outer 
membrane alone cannot completely account for the extent of antibiotic resistance in these 
bacteria.  Another mechanism is needed in addition to the membrane barrier in order to obtain 
these high levels of antibiotic resistance, a mechanism that has been shown to rely on the 
presence of efflux pumps [79, 82]. 
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1.8.3 Efflux Pumps 
Efflux pumps are present in all living organisms.  These pumps have the ability to actively 
export a wide variety of substances from cells including bile, hormones and host defence 
molecules [84].  Efflux pumps can be specific for one substrate or can transport a range of 
structurally dissimilar compounds such as antibiotics from different classes.  In bacteria, the 
pumps that transport several antibiotics can be associated with multidrug resistance (MDR) and 
consequently, they are known as multidrug resistance efflux pumps [79, 82, 84].  In bacteria, 
there are five families of MDR efflux pumps: the ATP-binding cassette (ABC) superfamily, the 
major facilitator superfamily (MFS), the multi-antimicrobial extrusion protein (MATE) family, 
the small multidrug resistance (SMR) family, and the resistance nodulation division (RND) 
superfamily [85].   
The ABC superfamily is one of the largest and oldest families of MDR efflux pumps and 
includes pumps such as LmrA from the Gram-negative bacterium Lactococcus lactis (see Figure 
1.6).  These transporters are present in all kingdoms of life, and utilize the energy of adenosine 
triphosphate (ATP) hydrolysis for efflux [85, 86].  The MFS is another large and old family of 
MDR efflux pumps.  These pumps are secondary transporters which are driven by chemiosmotic 
energy, and include proton/drug antiporters such as QacA from the Gram-positive bacterium 
Staphylococcus aureus (see Figure 1.6) [85].  The MATE family of MDR efflux pumps is the 
most recently discovered family of MDR efflux pumps.  These pumps are found in all kingdoms 
of life, and they are secondary transporters driven by the movement of sodium ions, and include 
Na+/drug antiporters such as NorM from the Gram-negative bacterium Vibrio parahaemolytic 
(see Figure 1.6) [85, 87].  The SMR family is a small family of MDR efflux pumps and includes 
H+/drug antiporters such as EmrR from Escherichia coli (see Figure 1.6).  The proton motive 
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force (PMF) drives these transporters through the movement of hydrogen ions [85, 88].  The 
RND superfamily is another smaller family of MDR efflux pumps.  These transporters are 
bacterial-specific and driven by the movement of hydrogen ions.  They are commonly found in 
Gram-negative bacteria and include proton-drug pumps such as the AcrAB-TolC system (efflux 
pumps comprised of AcrA, AcrB and TolC) from E. coli (see Figure 1.6) [82, 85].  Three genes 
are typically responsible for encoding these pumps.  The first gene encodes a membrane fusion 
protein that is associated with the cytoplasmic membrane such as AcrB.  The second gene 
encodes a transporter which allows for the export of the antibiotic across the inner membrane 
such as AcrA.  The third gene encodes an outer membrane protein that facilitates the passage of 
the antibiotic across the outer membrane such as TolC.  Together, these three proteins form a 
channel that crosses both the inner and outer membranes of the bacterium.  This allows the target 
antibiotic to be effluxed directly from the cytoplasm to the extracellular environment, a feature 
distinct from that encountered with the four other families of MDR efflux pumps [84, 89].  
Therefore, multidrug resistance in bacteria is due mainly to the presence of efflux pumps which 
are capable of actively exporting multiple antibiotics [79, 82, 84].   
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Figure 1.6: Multidrug resistance efflux pumps in bacteria.  Bacteria have five families of 
multidrug resistance efflux pumps: the major facilitator superfamily (MFS), the small multidrug 
resistance (SMR) family, the multi-antimicrobial extrusion protein (MATE) family, the 
resistance nodulation division (RND) superfamily, and the ATP-binding cassette (ABC) 
superfamily.  Figure taken from [85].  
1.8.4 β-Lactamases 
β-Lactam antibiotics are an important threat to the survival of bacteria since they inhibit cell wall 
synthesis resulting in the lysis and the death of the bacteria [50].  One of the most effective 
methods employed by bacteria to resist the devastating effects of β-lactam antibiotics is the 
production of enzymes capable of degrading/modifying β-lactam antibiotics.  These enzymes are 
known as β-lactamases and confer antibiotic resistance to bacteria by rendering β-lactam 
antibiotics inactive through the hydrolysis of the amide bond of the β-lactam ring [90, 91].  The 
β-lactamase enzymes are separated into four different classes in accordance with their amino 
acid sequence, and the nucleophile used in their enzymatic mechanism [90].  Classes A, C and D 
are serine β-lactamases since they employ a serine residue as the nucleophile (see Figure 1.7A).  
Class B β-lactamases, also termed metallo-β-lactamases (MBLs), contain zinc ion(s) in their 
active site (see Figure 1.7B) [92].  However, metal ions such as cobalt, cadmium or manganese 
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can also be employed by these enzymes in vitro [93].  MBLs represent the primary defence 
mechanism to β-lactam antibiotics in Gram-negative bacteria [94].    
 
 
 
Figure 1.7: Catalytic mechanism of β-lactamases.  A) The catalytic mechanism of serine β-
lactamases.  The hydroxyl group attached to the active site serine residue attacks the amide bond 
of the β-lactam ring producing an ester intermediate.  The hydroxyl group is regenerated 
following the hydrolysis of the ester.  B) The catalytic mechanism of dizinc metallo-β-
lactamases.  The hydroxide ion bridging both Zn2+ ions in the active site attacks the amide bond 
of the β-lactam ring, forming an oxyanion intermediate, which is stabilized by the Zn2+ ions.  
The oxyanion then attacks the water molecule bound to the second Zn2+ ion.  The hydroxide and 
the water molecules are both regenerated following elimination of the product.  Figure taken 
from references [53, 95]. 
1.9 Metallo-β-Lactamases 
MBLs are the most worrisome enzymes capable of conferring bacterial resistance to β-lactam 
antibiotics [96].  When they were originally discovered, MBLs were only found in a limited 
number of bacteria.  Since then, MBLs are being isolated from numerous Gram-negative bacteria 
such as Enterobacteriacea, Pseudomonas aeruginosa and multiple species of Acinetobacter [97].  
A reason for this rapid spread of MBLs is that over 75% of MBLs are plasmid-encoded, allowing 
them to be easily transferred from one bacterium to another [91, 97].  In addition, MBLs are 
A 
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insensitive to a large variety of common serine β-lactamase inhibitors such as clavulanic acid, 
sulbactam and tazobactam [92].  These β-lactamase inhibitors restore the activity of commonly 
used β-lactam antibiotics by adapting to the role of mechanism-based (sometimes referred to as 
suicide) inhibitors.  These inhibitors can irreversibly bind, and consequently inactivate serine β-
lactamases.  Therefore, when supplemented with these inhibitors, β-lactam antibiotics are 
capable of maintaining their bacteriostatic or bactericidal activity against serine β-lactamase-
producing bacteria.  However, MBLs are capable of cleaving these inhibitors, thus maintaining 
their catalytic activity against co-administered β-lactam antibiotics [92].  Furthermore, not only 
are MBLs capable of resisting β-lactam inhibitors, and inactivating all β-lactam antibiotics 
(except for monobactams), they are also known for their efficient carbapenemase activity [96].  
This is especially worrisome since carbapenems are the β-lactam antibiotics with the broadest 
spectrum of activity rendering them the last resort for many serious bacterial infections [96, 98].  
However, carbapenems are proving to be ineffective in the fight against the over 80 different 
MBLs that have presently been identified worldwide [91].    
MBLs are separated into three subclasses (B1, B2 and B3) based on their zinc coordination 
and sequence similarities.  Most MBLs are between 240 and 310 amino acid residues in length 
prior to the cleavage of the signal sequence (17 to 30 amino acids residues) to obtain the mature 
form of these enzymes [53].  The length of these MBLs varies due to insertions and deletions of 
amino acids.  However, the MBLs from all three classes can still be aligned through homologous 
secondary structure elements (e.g., α-helices and β-sheets) to create a standard numbering 
scheme for class B β-lactamases known as the BBL numbering scheme [99].  In addition to 
having similar sequence lengths, the MBLs from all three subclasses are typically monomeric 
(with few exceptions), and share a common four-layer crystal structure.  The four layers consist 
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of two central β-sheets flanked by two α-helices (see Figure 1.8).  This fold is typically called an 
α-β/β-α sandwich [53, 91, 93].  While this fold was originally discovered in MBLs, it can also be 
found in a range of other proteins such as glyoxalase II, lactonases, nitric oxide reductase and β-
hydroxylase [100–103].  Although the three MBL subclasses share similar fold and sequence 
length, they differ in their zinc coordination [53, 104].  Divalent zinc (Zn2+) plays an essential 
role in MBL catalysis since it is an efficient Lewis acid, has a flexible coordination geometry, 
and fast ligand exchange [53, 104].  MBLs possess two zinc binding site (Zn1 and Zn2), 
although not all MBLs are functional with two zinc ions (see Figure 1.8).  The catalytic activity 
of the majority of MBLs can be maintained whether the MBLs possess one zinc ion (monozinc 
form) or two zinc ions (dizinc or binuclear form).  In some cases, however, the presence of the 
second zinc ion has been shown to diminish the catalytic activity of the MBLs [91, 96].   
 
Figure 1.8: Active sites and crystal structures of metallo-β-lactamases.  Depicted are the active 
sites of BcII, CphA and L1 from metallo-β-lactamase subclasses B1, B2 and B3, respectively.  
Figure modified from reference [53].   
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1.9.1 Subclass B1 
Subclass B1 is the largest MBL subclass and includes well studied MBLs such as BcII from 
Bacillus cereus, CcrA from Bacteroides fragilis and NDM-1 from Klebsiella pneumoniae as well 
as SMP-1, IMP-1 and VIM-2 from Pseudomonas aeruginosa [93, 105–110].  The MBLs from 
subclass B1 share a sequence identity of over 23% as well as the broadest substrate specificity.  
These enzymes have the ability to cleave almost all β-lactam antibiotics including penicillins, 
cephalosporins and carbapenems.  However, subclass B1 enzymes are incapable of hydrolyzing 
monobactams [53, 96, 104].  Furthermore, all B1 enzymes are monomeric, and their active site is 
typically located at the edge of the β-sandwich of the α-β/β-α fold.  In addition, the zinc- 
coordinating ligands are highly conserved between the subclass B1 enzymes.  In the first zinc 
site (Zn1), also known as the 3H site, the metal is tetrahedrally coordinated to the side chains of 
three histidine residues (116, 118 and 196; BBL numbering), and to one water (or hydroxide) 
molecule (Wat1).  The second zinc site (Zn2), also known as the DCH site, binds zinc trigonal-
bipyramidally with aspartate 120, cysteine 221, histidine 263 and one water molecule (or 
hydroxide) (Wat1) serving as a ligand (see Figure 1.8).  The fifth ligand is usually another water 
(or a carbonate) molecule which is often referred to as the apical water (Wat2) [53, 104].  The 
water (or hydroxide) molecule (Wat1) bridging both zinc sites acts as the nucleophile which is 
necessary for the hydrolysis of the β-lactam ring.  This nucleophile attacks the carbonyl carbon 
atom of the β-lactam ring [91, 93].  Although, subclass B1 enzymes have two zinc binding sites, 
they demonstrate catalytic activity with either one or two zinc ions [53, 104].    
1.9.2 Subclass B2 
Subclass B2 includes MBLs such as CphA from Aeromonas hydrophila and ImiS from 
Aeromonas veronii [111, 112].  As in the case of B1 enzymes, all subclass B2 enzymes are 
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monomeric, but they only share an 11% sequence identity with subclass B1 enzymes [96].  
Unlike subclass B1, the subclass B2 enzymes are strictly carbapenemases, and demonstrate poor 
activity against penicillins, cephalosporins and monobactams.  Although their overall α-β/β-α 
fold shares the same characteristics as other MBLs, their active site groove is deeper and 
narrower.  This change in the position of the active site is believed to be the cause of the high 
specificity of these enzymes for carbapenems [53].  Furthermore, the Zn1 site of the B2 enzymes 
is formed by asparagine 116, histidine 118 and histidine 196.  The asparagine residue replaces 
histidine 116 in comparison to the Zn1 site of the subclass B1 enzymes [53, 104].  However, just 
as in the case of subclass B1, subclass B2 enzymes demonstrate a conserved Zn2 site which 
coordinates zinc with aspartate 120, cysteine 221 and histidine 263 (see Figure 1.8) [104].  
Although B2 enzymes still possess two zinc binding sites, they are typically active with one zinc 
ion only since the binding of the second zinc ion has been shown to inhibit the activity of these 
enzymes [53, 104].     
1.9.3 Subclass B3 
Subclass B3 includes MBLs such as L1 from Stenotrophomonas maltophilia and FEZ-1 from 
Legionella gormanii [113, 114].  Distinct from B1 and B2 subclasses, B3 enzymes can be either 
monomeric (e.g., FEZ-1) or multimeric (e.g., L1, which is tetrameric) [96, 115].  Subclass B3 
proteins only have nine conserved residues when compared to both B1 and B2 enzymes [96].  
Similar to subclass B1, the subclass B3 MBLs are capable of cleaving most β-lactam antibiotics 
(i.e., penicillins and cephalosporins) except for monobactams.  However, the B3 enzymes are 
less efficient in hydrolyzing carbapenems when compared to both other subclasses of MBLs 
[53].  Nevertheless, like subclass B1 enzymes, the Zn1 site of B3 proteins coordinate zinc using 
histidine residues 116, 118 and 196 (BBL numbering) and a water molecule [104].  The Zn2 site 
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coordinates the zinc ion trigonal-bipyramidally with aspartate 120, histidine 121, histidine 263, 
and two water molecules (histidine 121 replaces cysteine 221 in comparison to the Zn2 site of 
the subclass B1 enzymes; see Figure 1.8).  Although subclass B3 enzymes have two zinc binding 
sites, they demonstrate significant catalytic activity with one zinc ion [53, 104].   
1.10 MBLs of Clinical Importance 
1.10.1 NDM-1 
In 2008, a previously unknown MBL was isolated from the Gram-negative bacteria Klebsiella 
pneumoniae and Escherichia coli [116, 117].  This bacterium was recovered from a Swedish 
patient of Indian origin who caught a urinary tract infection after receiving treatment in a 
hospital in New Delhi, India.  This unknown MBL was designated the New Delhi metallo-β-
lactamase (NDM-1) and was classified as a B1 enzyme [117, 118].  Since its isolation in 
Sweden, NDM-1 has rapidly spread around the globe being isolated in numerous countries 
including the United States of America, Canada, the United Kingdom, France, Germany, Japan 
and China.  NDM-1 easily spread worldwide since, like many MBLs, NDM-1 is plasmid-
encoded, and can be easily transferred between different bacterial strains [51, 119].  
Furthermore, the plasmid harbouring the NDM-1 gene is quite large (180 kb for K. pneumoniae 
and 140 kb for E. coli), and contains resistance genes to almost all β-lactam antibiotics making 
NDM-1 a serious health threat [116].  In 2009, the Health Protection Agency issued a national 
alert due to the growing concern revolving around the rapid spread of NDM-1 [117].   
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Figure 1.9: Active site of NDM-1.  NDM-1 has two zinc ions (green): one in the 3H site and the 
other in the DCH site.  The key amino acid residues for zinc-binding are coloured red.     
NDM-1, similar to most MBLs, is a monomer composed of 270 amino acid residues and a 
signal peptide of 28 amino acid residues.  In addition, similar to most MBLs from subclass B1, 
NDM-1 contains two zinc ions (one in the 3H site and the other in the DCH site; see Figure 1.9) 
located in an active site at the edge of the two β-sheets of the typical α-β/β-α fold.  However, 
contrary to other MBLs from subclass B1, the structure of NDM-1 presents an open, large and 
flexible active site.  It is thought that this modified active site allows NDM-1 to have the ability 
to hydrolyze an increased number of β-lactam antibiotics is comparison to other MBLs [51].  
Therefore, it is not surprising that NDM-1 possesses a very low sequence identity with other 
MBLs.  The MBLs that demonstrate the highest similarity with NDM-1 are VIM-2 and IMP-1, 
with 32% sequence identity [91]. 
1.10.2 VIM-2 
MBL subclass B1 contains a variety of enzymes, but none are as prevalent as VIM (Verona 
integrin-encoded metallo-β-lactamase).  VIM, more specifically VIM-1, was originally isolated 
from Pseudomonas aeruginosa in Verona, Italy in 1997 [110, 120].  Since the VIM enzymes are 
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subclass B1 enzymes, they possess the ability to cleave most β-lactam antibiotics including 
penicillins, cephalosporins and carbapenems [110, 121].  However, VIM, similar to many other 
MBLs, is incapable of hydrolyzing monobactams [58, 110].  Currently, 11 different types of 
VIM enzymes (VIM-1 to VIM-11a and -11b) have been isolated worldwide [120].    
 
Figure 1.10: Active site of VIM-2.  The active site contains two zinc ions (depicted in green) 
which are coordinated by the 3H and the DCH sites.  A water molecule (shown in red) bridges 
the two zinc ions.  A Cl- ion, bound to the Zn2+ ion in the DCH-site (depicted in yellow), is an 
artifact of the crystallization procedure.  Figure adapted from reference [110]. 
The VIM enzyme that was studied during this research project is VIM-2.  VIM-2 shares a 
90% amino acid sequence identity with the originally discovered VIM-1 enzyme.  VIM-2 was 
originally isolated in P. aeruginosa in France in 1996 [120].  VIM-2 is an MBL with a molecular 
mass of 25.5 kDa, and contains 240 amino acids in its mature form.  In its native, reduced form, 
VIM-2 possesses two zinc ions in its active site: one in the 3H site and the other in the DCH site.  
These two zinc ions are bridged by a water molecule (see Figure 1.10) [110].  Furthermore, 
VIM-2 is currently the most commonly isolated MBL in the clinical environment as well as the 
most widespread MBL [122], rendering VIM-2 the primary target for this MBL research.          
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1.10.3 IMP-1 
The IMP enzymes (subclass B1) are thought to be the most dangerous MBLs.  IMP genes are 
located on two mobile bacterial genetic elements: plasmids and integron cassettes.  Therefore, 
these two mobile elements allow the IMP enzymes to be easily and rapidly transferred among 
different bacteria [93, 123].  Currently, 18 different types of IMP enzymes (IMP-1 to IMP-18) 
have been isolated from numerous bacterial strains [120]. 
 
Figure 1.11: Active site of IMP-1.  The active site of IMP-1 contains two zinc ions (depicted in 
green) which are coordinated by the 3H and the DCH sites.  A water molecule (shown in red) 
bridges the two zinc ions.  Figure adapted from reference [93].  
The IMP enzyme that was the focus of this research project is IMP-1.  IMP-1 was originally 
isolated from Pseudomonas aeruginosa in Japan in 1988 [90, 120].  In 1991 and 1993, IMP-1 
was once again isolated in Japan, but from the Gram-negative bacterium Serratia marcescens 
[120].  This (rapid) spread of IMP-1 between different bacterial strains is a result of the IMP-1 
genes being encoded by both plasmids and integrons.  Currently, IMP-1 is being isolated from 
multiple bacterial species including Pseudomonas, Serratia, Acinebacter and Klebsiella [93, 120, 
123].  IMP-1 is an MBL with a molecular mass of 25 kDa, and contains 228 amino acid residues 
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in its mature form.  IMP-1 was shown to contain two zinc ions in its active site (see Figure 1.11), 
and shares a 31% sequence identity with VIM-2 [90, 110].  
1.11 Cationic Peptides 
To this day, there are still no clinically approved inhibitors for MBLs.  The inability to design 
MBL inhibitors is a direct consequence of the diversity of the active sites that differentiate one 
MBL from another [90, 91].  However, previous (unpublished) studies have demonstrated that 
cationic peptides may possibly have the ability to inhibit MBLs.  The usage of these cationic 
peptides as potential inhibitors of MBLs was discovered accidentally by a student of Dr. 
Siemann’s group at Laurentian University (Sudbury, Ontario, Canada).  This student noticed that 
IMP-1 was inhibited by a common substrate of the anthrax lethal factor, a zinc-dependent 
endopeptidase [124].  The structure of this peptide, the anthrax lethal factor protease substrate 
(S-pNA), is Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-pNA [125].  Following this discovery, Dr. 
Dmitrienko’s group at the University of Waterloo (Waterloo, Ontario, Canada) discovered that 
the cationic peptide was also a potent inhibitor of VIM-2.   
It is puzzling that a peptide would be able to inhibit these enzymes because of the 
stereochemistry of the active site.  β-Lactams imitate the D-Ala-D-Ala configuration, while the 
cationic peptides are in the L, L configuration.  A better understanding of the molecular basis for 
the interaction of peptides with MBLs could potentially lead to the development of novel MBL 
inhibitors. 
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Chapter 2: Thesis Objectives 
With the wide-spread emergence of microbial antibiotic resistance due to the production of 
MBLs, new inhibitors of these enzymes must be developed as no clinically approved inhibitors 
currently exist for MBLs.  However, preliminary studies on cationic peptides have demonstrated 
their potential to inhibit MBLs.   
Hence, the objective of this study was to determine the structure-activity relationship between 
subclass B1 metallo-β-lactamases, VIM-2 and IMP-1, and cationic peptides.  This relationship 
was investigated through the assessment of the inhibitory potency of a variety of peptides 
bearing cationic residues, the examination of the effect of different β-lactam substrates on 
peptide-mediated inhibition, the evaluation of the inhibition of enzyme function in the presence 
of salts (which could interfere with inhibition), and the determination of the mechanism of 
inhibition. 
A better understanding of the structure-activity relationship between metallo-β-lactamases 
and cationic peptides could be exploited for the development of novel MBL inhibitors for 
potential clinical use.  
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Chapter 3: Materials and Methods 
3.1 Chemicals  
Chemicals were obtained as indicated in Table 3.1, and were of the highest grade available.  All 
peptides were custom-synthesized by Biomatik Corp. (Cambridge, Ontario, Canada) except for 
peptides 11 and 17, which were purchased from EMD Millipore Corp. (Bellerica, Massachusetts, 
U.S.A.) and Bachem AG (Bubendorf, Switzerland), respectively (see Table 3.2).  All other 
chemical were obtained from Bioshop Canada Inc. (Burlington, Ontario, Canada).   
Table 3.1: Chemicals listed according to their suppliers. 
Supplier Reagent 
AMRESCO LLC. 
(Solon, Ohio, U.S.A.) 
β-mercaptoethanol (BME) 
AK Scientific Inc. 
(Mountain View, California, U.S.A.) 
Ceftazidime 
BDH Inc. 
(Toronto, Ontario, Canada) 
Sodium sulfate (Na2SO4) 
Brenntag Canada Inc. 
(Toronto, Ontario, Canada) 
Hydrochloric acid (HCl) 
Caledon Laboratories Ltd. 
(Georgetown, Ontario, Canada) 
Dimethyl sulfoxide (DMSO) 
Dr. Gary Dmitrienko (Department of 
Chemistry, University of Waterloo, 
Waterloo, Ontario, Canada) 
Metallo-β-lactamases (IMP-1 and VIM-2) 
UW substrates (UW-57 and UW-58) 
EMD Millipore Corp. 
(Bellerica, Massachusetts, U.S.A.) 
Milli-Q ultrapure water (≥ 18.2 MΩ cm resistivity)  
Life Technologies Inc. 
(Burlington, Ontario, Canada) 
Alexa Fluor 488 C5-maleimide 
Alexa Fluor 546 C5-maleimide 
Macherey-Nagel GmbH & Co. KG 
(Düren, Germany) 
POLYGRAM CEL 300 AC-10% (Fibrous cellulose with 10% 
acetylated cellulose on polyester sheet for TLC) 
Merck Research Laboratories 
(Rahway, New Jersey, U.S.A.) 
Imipenem 
Oxoid Ltd. 
(Basingstoke, Hampshire, England) 
Nitrocefin 
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Sigma-Aldrich Co. 
(St-Louis, Missouri, U.S.A.) 
2,6-pyridinedicarboxylic acid (Dipicolinic acid) 
4-(2-pyridylazo)resorcinol (PAR) 
5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) 
Benzylpenicillin 
Bovine Serum Albumin, further purified fraction V (BSA) 
Calcium chloride (CaCl2) 
Cefoxitin 
Cephaloridine 
Cephalosporin C 
Cephalothin 
Chelex 100 sodium 
Cystamine dihydrochloride 
Triton X-100 
Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, U.S.A.) 
Bromophenol Blue 
Magnesium sulfate (MgSO4) 
Pierce NHS-Activated agarose resin 
Pierce 660 nm Protein Assay reagent 
Sodium bromide (NaBr) 
Tris(2-carboxyethyl)phosphine (TCEP) 
Zinc Sulfate (ZnSO4) 
Table 3.2: Peptides employed as MBL inhibitors.  The concentrations of the peptides containing 
a para-nitroanilide (pNA) group were determined by measuring their absorbance at 342 nm (ε342 
= 8,270 M-1 cm-1) [125].  The concentrations of peptides containing either tyrosine or cystine 
residues (ε280 = 1,490 M-1 cm-1 and 125 M-1 cm-1, respectively) were determined by measuring 
their absorbance at 280 nm.     
Peptide MW (g/mol) ε (M-1 cm-1) 
1 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-pNA 2,089.30 8,270 
2 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Pro-pNA 2,030.28 8,270 
3 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-NHOH 1,984.40 1,490 
4 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 1,969.36 1,490 
5 Ac-Gly-Tyr-βAla-(Arg)7-Val-Leu-Arg-OH 1,813.17 1,490 
6 Ac-Gly-Tyr-βAla-(Arg)6-Val-Leu-Arg-OH 1,656.98 1,490 
7 Ac-Gly-Tyr-βAla-(Arg)5-Val-Leu-Arg-OH 1,500.79 1,490 
8 Ac-Gly-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 1,344.60 1,490 
9 Ac-Nle-(Lys)4-Val-Leu-Pro-pNA 1,115.42 8,270 
10 Ac-Nle-(Arg)4-Val-Leu-Arg-OH 1,166.45 ― 
11 Poly-arginine  10,000.00 ― 
12 Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 1,390.68 1,490 
13 
Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 
             │ 
Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 
2,779.36 3,105 
14 Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 2,014.44 1,490 
15 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
             │ 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
4,026.88 3,105 
16 Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Cys-OH 1,962.39 1,490 
17 Ala-Pro-pNA 342.78 8,270 
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3.2 Preparation of Solutions 
3.2.1 Preparation of Buffers and Salt Solutions 
HEPES buffers were prepared by adding 0.477 g, 1.192 g and 2.383 g of HEPES (acid form) to 
100 mL of Milli-Q water to yield final concentrations of 20 mM, 50 mM and 100 mM, 
respectively.  The pH of the buffers was adjusted to 7.0, 7.2 or 7.4 with the aid of NaOH (5 M). 
Tris buffers at concentrations of 0.5 M and 1.5 M were obtained by dissolving 6.057 g and 
18.171 g of Tris (base) in 100 mL of Milli-Q water, respectively.  The pH was decreased to 6.8 
or 8.9 using HCl (5 M). 
Phosphate-buffered saline (PBS) at a concentration of 0.1 M was prepared by combining 0.1 
M of Na2HPO4 and 0.1 M of NaH2PO4 in a ratio that permitted the buffer to achieve a final pH 
of 7.2. 
Salts were typically prepared as 100 mM stock solutions in 10 mL of HEPES buffer (50 mM, 
pH 7.0) except for guanidine hydrochloride (GdnHCl).  GdnHCl was prepared as an 8 M stock 
solution by combining 76.424 g of GdnHCl, 42.856 g of Milli-Q water and 1.192 g of HEPES 
(acid form).  The pH of the GdnHCl stock solution was adjusted to 7.4 with the aid of NaOH (5 
M).  
3.2.2 Preparation of Substrates 
The UW substrates were prepared as 2 mM stock solutions by initially dissolving 4.3 mg and 4.5 
mg of UW-57 and UW-58, respectively, in 250 μL of DMSO.  A 2 mM stock solution of 
nitrocefin was obtained by dissolving 5.2 mg of nitrocefin in 250 μL of DMSO.  A volume of 
4.75 mL of HEPES buffer (50 mM, pH 7.0) was added to each substrate stock solution while 
being vortexed (to prevent the precipitation of the substrate).  The substrate stock solutions were 
then separated into 1 mL aliquots.  Since these substrates are light sensitive, all containers were 
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wrapped in aluminium foil to protect the aliquots from light.   Finally, the aliquots were stored at 
-20 °C until use. 
All other substrates were typically prepared as 2 mM stock solutions in 10 mL of HEPES 
buffer (50 mM, pH 7.0), and kept at -20 °C until use. 
3.2.3 Preparation of Peptides 
The peptides listed in Table 3.2 were typically prepared by dissolving 1 mg of peptide in 1 mL of 
HEPES buffer (50 mM, 7.0) except for Ala-Pro-pNA (peptide 17) and poly-arginine (peptide 
11).  A 50 mM stock of Ala-Pro-pNA was obtained by dissolving 19.6 mg (taking into account 
the 14.3% salt content) of the peptide in 1 mL of 95% (v/v) ethanol.  Poly-arginine was prepared 
as a 1 mM stock solution by dissolving 5.0 mg of the peptide in 500 µL of HEPES buffer (50 
mM, pH 7.0).   
The concentrations of the peptides were determined with a Biochrom Ultrospec 2100 pro 
UV/Visible Spectrophotometer (Biochrom Ltd., Cambridge, United Kingdom) or a Cary-60 
Spectrophotometer (Agilent Technologies Canada Inc., Mississauga, Ontario, Canada) at a 
wavelength of 280 nm except for the peptides containing a para-nitroanilide (pNA) group where 
a wavelength of 342 nm was used.  The extinction coefficients of the peptides were used to 
calculate their concentrations (see Table 3.2).   
The disulfide-containing peptides were prepared by leaving the cysteine-containing peptide 
stock solution in an open 1.5 mL centrifuge tube for three days at room temperature.  After three 
days, a two-fold excess of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) was added to an aliquot 
of the reaction mixture to verify that the peptides were oxidized.  DTNB has the ability to react 
with free thiol groups (see section 3.8).  Thus, when the peptides were oxidized, no free thiol 
groups remained in the solution.    
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3.2.4 Preparation of the Alexa Fluor Dyes 
Alexa Fluor fluorescent dyes were used for the labeling of VIM-2 and the cysteine-containing 
(Arg)8 core peptide [Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH; peptide 14 in Table 3.2].  Two 
different dyes were employed for the labeling: Alexa Fluor 488 and Alexa Fluor 546.  Prior to 
their usage, 1 mg of the Alexa Fluor dyes was dissolved in 100 µL of DMSO.  Since the Alexa 
Fluor dyes are extremely sensitive to light, all tubes were wrapped in aluminium foil to protect 
the solutions from light.  The concentrations of the Alexa Fluor stock solutions (25.8 mM for 
Alexa Fluor 488, and 18.1 mM for Alexa Fluor 546) were determined spectrophotometrically at 
λmax (492 nm for Alexa Fluor 488, and 553 nm for Alexa Fluor 546) using the appropriate 
extinction coefficients.  The extinction coefficient of Alexa Fluor 488 is 73,000 M-1 cm-1 at 492 
nm while that of Alexa Fluor 546 is 120,000 M-1 cm-1 at 553 nm.  All stock solutions were kept 
at -20 °C prior to use.   
3.2.5 Preparation of Enzyme Stock Solutions 
Two VIM-2 enzyme stock solutions were obtained from Dr. Dmitrienko’s laboratory: one stock 
had a concentration of 35 µM while the other stock had a concentration of 93 µM.  The 
concentrations of the VIM-2 stock solutions were determined spectrophotometrically at 280 nm 
using an extinction coefficient (ε280) of 28,500 M-1 cm-1 [126]. 
 For activity assays, an intermediate VIM-2 stock solution was prepared in a final volume of 
200 µL.  A volume of 0.7 µL of VIM-2 (35 µM) was diluted in HEPES buffer (50 mM, pH 7.0) 
to obtain a final VIM-2 concentration of 120 nM.  This intermediate VIM-2 stock solution was 
also supplemented with 20 µM ZnSO4 to ensure maximum enzyme activity. 
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 The IMP-1 enzyme stock solution (626 µM) was supplied by Dr. Dmitrienko (University of 
Waterloo). The concentration of the IMP-1 stock solution was determined 
spectrophotometrically at 280 nm using an extinction coefficient (ε280) of 44,380 M-1 cm-1 [127]. 
 After determining its concentration, the entire IMP-1 enzyme stock solution was diluted with 
390 µL of glycerol and 382.5 µL of HEPES buffer (100 mM, pH 7.2), yielding an 8 µM stock 
solution in 50% glycerol (v/v).  The stock solution was then separated into 200 µL aliquots, and 
kept at -20 °C until use. 
For activity assays, an intermediate IMP-1 stock solution was prepared in a final volume of 
100 µL.  A volume of 0.5 µL of IMP-1 (8 µM) was diluted in HEPES buffer (50 mM, pH 7.2) to 
obtain a final IMP-1 concentration of 40 nM.  This intermediate IMP-1 stock solution was 
supplemented with 1 mM ZnSO4 to ensure maximum enzyme activity, and with 1 mg/mL BSA 
as well as 0.01% (w/v) Triton X-100 to prevent enzyme aggregation/denaturation. 
3.3 MBL Activity Assays 
Typical MBL activity assays were performed in a final assay volume of 100 μL using nitrocefin 
as the substrate.  Prior to initiation of the assays, the enzyme was pre-incubated at room 
temperature in 50 mM HEPES buffer (pH 7.0 for VIM-2 and pH 7.2 for IMP-1) for 1 min.  
Typically, 5 μL of an intermediate enzyme stock solution (120 nM for VIM-2 and 40 nM for 
IMP-1) was added to 90 µL of HEPES buffer.  Following incubation, 5 μL of nitrocefin (2 mM) 
was added to the solution to achieve a final nitrocefin concentration of 100 μM.  The progress of 
the reaction was measured at a wavelength of 482 nm using a Biochrom or a Cary-60 
spectrophotometer.  Kinetic parameters were obtained by determining the slopes of the initial 
linear portions of the progress curves (typically, the first 20 s to 30 s).   
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Assays performed with substrates other than nitrocefin followed the general assay protocol 
described above.  Similar to nitrocefin, these substrates were employed at a final concentration of 
100 µM in the assay except for benzylpenicillin and imipenem which were used at 
concentrations of 350 µM and 45 µM, respectively.  Substrates were employed at these 
concentrations since the concentrations were approximately five-fold higher than the Michaelis 
constant of the substrates.  Furthermore, for nitrocefin-like substrates, such as UW-57 and UW-
58, the procedure remained identical with the absorbance being measured at 482 nm.  For 
substrates such as cephaloridine, cephalothin, ceftazidime, cephalosporin C and cefoxitin, the 
absorbance was measured at a wavelength of 260 nm. In the case of benzylpenicillin and 
imipenem, the absorbance was measured at a wavelength of 235 nm and 300 nm, respectively.   
Assays in the presence of inhibitors were performed as outlined above except that the 
inhibitor was mixed with the HEPES buffer prior to the addition of the enzyme.  By varying the 
inhibitor concentrations throughout the assays, the concentration of inhibitor required to inhibit 
50 % of enzyme (IC50 value) was determined.    
 For assays used in the determination of the inhibition constant and the mode of inhibition, the 
same general assay as described above was employed.  However, both the substrate and inhibitor 
concentrations were varied.  The final substrate concentrations in the assays were 12 μM, 20 μM, 
25 μM, 33 μM, 50 μM and 100 μM.  Using the data analysis software GraFit4 (Erithacus 
Software Ltd., Surrey, United Kingdom), the kinetic parameters were determined by fitting the 
velocity data obtained from the assays to either equations 3.1 or 3.3, 
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where v is the velocity, Vmax represents the maximum velocity, [S] denotes the concentration of 
substrate, [I] is the concentration of the inhibitor, KM represents the Michaelis constant, Ki 
denotes the inhibition constant and Ki′app is (k3/k2)Ki′ (see Figure 4.2).  Equations 3.1 and 3.2 
represent the velocity equation and the corresponding Lineweaver-Burk expression, respectively, 
for the mechanism involving the production of an enzyme-product-inhibitor ternary complex 
[128].  On the other hand, equations 3.3 and 3.4 denote the velocity equation and the 
corresponding Lineweaver-Burk expression for hyperbolic (partial) mixed-type inhibition [129]. 
3.4 Stopped-flow Studies 
All stopped-flow studies were conducted in 50 mM HEPES buffer (pH 7.0) and at a temperature 
of 20°C using an OLIS spectrophotometry system equipped with a U.S.A. two-syringe stopped-
flow device.  For single-turnover experiments, 20 µM of VIM-2 was rapidly mixed with 20 µM 
of nitrocefin.  For double-turnover measurements, only 10 µM of VIM-2 was combined with 20 
µM of nitrocefin.  Absorbance changes that occurred during the reaction were monitored from 
350 nm to 575 nm, and from 475 nm to 700 nm for 1.2 s.  The single and double-turnover 
experiments were repeated using 50 µM and 10 µM of the cationic peptide inhibitor, 
respectively.  Since the OLIS spectrophotometry system only possessed a two-syringe stopped-
flow device, the inhibitor needed to be pre-exposed to one of the reagents before taking 
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measurements.  Therefore, the inhibitor was pre-exposed to both the enzyme and the substrate in 
two separate measurements.  The rate constants of the reactions were determined by fitting the 
stopped-flow data to the appropriate enzyme kinetic model using the kinetic data analysis 
software OLIS GlobalWorks (OLIS Inc., Bogart, Georgia, U.S.A.). 
3.5 MBL UV-Vis Wave Scans  
All MBL UV-Vis wave scans were performed in a final volume of 100 µL.  Prior to the initiation 
of the scans, the VIM-2 enzyme (at a final concentration of 1 µM) was pre-incubated in the 
absence and presence of peptide inhibitors (5 µM) at room temperature in HEPES buffer (50 
mM, pH 7.0) for 1 min.  Following the incubation, the spectra were measured from 250 nm to 
400 nm using a Cary-60 spectrophotometer.  Furthermore, 25 mM Na2SO4 was occasionally 
added to the VIM-2/inhibitor mixture to determine the effect of salt on the interaction between 
the enzyme and the cationic peptides.   
3.6 Electrophoresis 
3.6.1 Native Polyacrylamide Gel Electrophoresis (PAGE) 
Native polyacrylamide gel electrophoresis was utilized to study the interaction between VIM-2 
and the cationic peptides.  Each gel was composed of a resolving portion containing 15% 
acrylamide as well as a stacking portion which was poured over the resolving gel once the latter 
was solidified (see Table 3.3 for composition of gels).  After the polymerization of the gel, 10 µL 
of the samples were loaded into the sample wells at the top of the stacking gel.  The samples 
were prepared by 1:2 dilution of 1 mg/mL BSA or 10 µM VIM-2 in the absence and the presence 
of 100 µM of the (Arg)5 or (Arg)8 core peptides (peptides 7 and 4, respectively) in 1X native 
sample buffer (see Table 3.4 for composition).   
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Table 3.3: Reagents used in the preparation of the resolving and stacking gels. 
Reagent Resolving Gel Stacking Gel 
30% (w/v) Acrylamide/Bis-
acrylamide (37.5:1) 30% solution 5.20 mL 1.00 mL 
Tris-HCl (1.5 M, pH 8.9) 2.80 mL ― 
Tris-HCl (0.5 M, pH 6.8) ― 2.50 mL 
Milli-Q Water 3.42 mL 6.40 mL 
10% (w/v) APS 60 µL 100 µL 
TEMED 15 µL 10 µL 
Table 3.4: Reagents employed in the preparation of the native sample buffer.  The volumes 
indicated allowed for the preparation of 10 mL of a 5X sample buffer. 
Reagent Volume (mL) 
Glycerol 4.84 
Tris-HCl (0.5 M, pH 6.8) 2.06 
Milli-Q Water 2.61 
0.1% (w/v) Bromophenol Blue 0.49 
Once the samples were loaded, the gel was placed in a Bio-Rad Mini-PROTEAN Tetra 
Electrophoresis System (Bio-Rad Laboratories Ltd., Mississauga, Ontario, Canada) and the 
chamber was filled with native running buffer (see Table 3.5 for composition) that was prepared 
directly before use.  The electrophoresis was performed at 100 V for 45 min. 
Table 3.5: Reagents used in the preparation of the native running buffer.  The pH value of the 
running buffer was adjusted to 8.9 with NaOH (5 M) before use. 
Reagent Amount 
Glycine 66.5 g 
Tris 15.1 g 
Milli-Q Water 500 mL 
Following electrophoresis, the gels were stained with Coomassie Brilliant Blue R-250 in 
order to visualize the protein bands.  The Coomassie Blue solution was prepared with 0.2% (w/v) 
Coomassie Brilliant Blue R-250 in an aqueous solution containing 45.5% (v/v) methanol and 
9.1% (v/v) glacial acetic acid.  The gels were submerged in the Coomassie Blue solution for 2 h 
on a ROCKER II rocking platform mixer (Boekel Scientific, Feasterville, Pennsylvania, U.S.A.).  
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Following staining, the gels were destained using an aqueous destaining solution consisting of 
45.5% (v/v) methanol and 9.1% (v/v) glacial acetic acid.  The gels were subjected to three 
exchanges in the destaining solution.  Following the third exchange, the gels were left overnight 
in the destaining solution at room temperature in order to obtain a more evenly destained 
background.  After the destaining, the gels were stored in a solution of 10% (v/v) glacial acetic 
acid at 4 °C.  Densitometry was conducted to quantify the intensity of the protein bands using the 
gel imaging software AlphaEase (Alpha Innotech Corp., San Leandro, California, U.S.A.).   
3.6.2 Paper Electrophoresis 
Paper electrophoresis was conducted to study the interaction between VIM-2 and the cationic 
peptides.  Thin layer chromatography (TLC) sheets were utilized as the supporting medium for 
the electrophoresis and were cut into strips measuring 5 cm in width and 7 cm in length.  Prior to 
electrophoresis, the TLC paper was equilibrated with 50 mM HEPES buffer (pH 7.0) followed 
by an equilibration with 20 µM of nitrocefin.  Once the TLC paper was completely soaked with 
nitrocefin, 1 µL of the samples was added to the center of the TLC paper.  The samples 
contained 10 µM of VIM-2 and/or 100 µM of the (Arg)8 core peptide (peptide 4).  Following the 
addition of the samples to the TLC paper, the negative electrode alligator clip was attached to 
one side of the TLC paper while the positive electrode alligator clip was attached to the other 
side.  The electrophoresis was performed at 120 V for 6 min using an Owl EC-105 Compact 
Power Supply (Thermo Fisher Scientific Inc., Waltham, Massachusetts, U.S.A.).    
3.7 Peptide Labeling and Purification 
3.7.1 Peptide Labeling Procedure 
Peptide labeling was usually conducted in a final volume of 400 µL.  To commence the labeling 
process, 40 µM of the (Arg)8Cys core peptide (peptide 14 in Table 3.2) was dissolved in HEPES 
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buffer (50 mM, pH 7.2) at room temperature.  A 10-fold molar excess of tris(2-
carboxyethyl)phosphine (TCEP) was subsequently added in order to reduce any disulfide bonds 
which may have been present in the peptide solution.  A sufficient amount of the Alexa Fluor 
dye was then added dropwise from the stock solution to obtain a 10 to 20-fold molar excess of 
dye for each mole of peptide (i.e., 400 µM to 800 µM).  After addition of the dye, the mixture 
was incubated for 2 h at room temperature, or overnight at 4 °C.  Upon completion of the 
reaction, the excess dye was removed from the labeled peptide solution as outlined below.  
3.7.2 Peptide Purification Procedure 
Following peptide labeling, the excess dye needed to be removed from the solution.  The most 
commonly used method for the removal of the dye is HPLC.  However, initial attempts to purify 
the labeled peptide solution failed, presumably in view of the small quantities of peptide and dye 
employed.  Therefore, a new technique was developed to allow for the purification of the 
solution.  This method achieved the purification of the labeled peptide using cystamine and 
NHS-Activated agarose (Thermo Fisher Scientific, Waltham, Massachusetts, U.S.A.).  The 
NHS-Activated agarose resin contains an N-hydroxysuccinimide (NHS) ester functional group 
which can react with primary amines to form stable amide linkages.  Furthermore, cystamine is a 
small disulfide with two terminal amine functional groups.  Therefore, the resin can interact with 
the amine functional group(s) of cystamine (see Figure 3.1).  Once cystamine was coupled to the 
resin, its disulfide bond was reduced by TCEP to generate a free sulfhydryl group (see Figure 
3.1).  In the end, the maleimide group of the excess Alexa Fluor dye can covalently bind the free 
sulfhydryl group on the cysteamine-coupled resin.  Consequently, the resin would allow for the 
removal of excess dye from the labeled peptide solution.       
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Figure 3.1: Preparation of the cysteamine-coupled agarose resin.  In the first step, cystamine 
reacts with the NHS functional group on the agarose resin forming a stable amide bond.  For the 
second step, TCEP is added to the solution to reduce the disulfide bond generating a free 
sulfhydryl group.  This resin can then be used to scavenge thiol-reactive molecules such as the 
Alexa Fluor dyes. 
Experimentally, for the purification of the labeled peptide solution, 66 mg of the NHS-
Activated agarose resin was placed into an empty 800 µL centrifuge column (Thermo Fisher 
Scientific, Waltham, Massachusetts, U.S.A.).  Next, 400 µL of 0.5 M cystamine (pH 7.4) was 
added to the column.  Once cystamine was added, the column was mixed end-over-end using a 
Roto-Torque fixed speed heavy duty rotator (Cole-Parmer Instrument Co., Chicago, Illinois, 
U.S.A.) for 1 h to 2 h at room temperature, or overnight at 4 °C.  Following incubation, the 
column was centrifuged at 1,000 × g for 1 min.  After centrifugation, 400 µL of HEPES buffer 
TCEPO
TCEP
Cysteamine
NHS-Activated Agarose Cystamine
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(50 mM, pH 7.0) was added to the column, and subsequently centrifuged at 1,000 × g for 1 min.  
This process (wash step) was repeated twice.      
Once cystamine was coupled to the agarose, 400 µL of TCEP (10 mM) was added to the 
resin.  The column was then mixed end-over-end for 10 min using a Roto-Torque rotator.  Once 
the reduction was complete, the column was centrifuged at 1,000 × g for 1 min, and the flow-
through was saved.  The complete removal of TCEP was ascertained by adding DTNB to the 
filtrate(s) (after 12 spins).   
Once TCEP was removed from the column, 400 µL of the Alexa Fluor labeled peptide 
solution was added to the cysteamine-coupled resin.  The column was then mixed end-over-end 
for one hour using the Roto-Torque rotator.  Once the incubation was complete, the column was 
centrifuged at 1,000 × g for 1 min to recover the labeled peptide in the filtrate.   
Following purification, the concentration of the labeled peptide was calculated using equation 
3.9, 
 c = A280 – (Amax –CǤFǤሻ
εP
× Ǥ	Ǥ (Equation 3.9) 
where c is the concentration of the peptide, A280 indicates the absorbance of the labeled peptide 
at 280 nm, Amax denotes the maximum absorbance of the labeled peptide at the absorbance 
maximum of the fluorescent dye (492 nm for Alexa Fluor 488 and 553 nm for Alexa Fluor 546), 
C.F. represents the correction factor of the dye at 280 nm (0.11 for Alexa Fluor 488 and 0.12 for 
Alexa Fluor 546), εP denotes the extinction coefficient of the peptide, and D.F. is the dilution 
factor.  In the equation, the correction factor accounted for the amount of absorbance caused by 
the dye at 280 nm while the dilution factor accounted for the extent to which the labeled peptide 
solution was diluted prior to the absorbance measurement.  
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3.8 Preparation of Mononuclear VIM-2  
The preparation of mononuclear VIM-2 was achieved following the protocols reported by 
Gardonio and Siemann for the generation of mononuclear IMP-1 [130].  For the generation of 
mononuclear VIM-2, the first step encompassed the chemical modification of the zinc-bound 
cysteine residue through the addition of 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) in the 
presence of dipicolinic acid (DPA) (see Figure 3.2).  The second step incorporated the release of 
 
Figure 3.2: Schematic representation of the removal of the cysteine-bound Zn2+ from VIM-2.  
The first step incorporates the modification of the cysteine residue of the enzyme, represented by 
E-S--Zn2+, in the presence of DPA.  The second step involves the release of the modifying group 
from the cysteine residue through the reduction of the disulfide bond by TCEP.  Both reaction 
steps can be followed spectrophotometrically at 412 nm in view of the release of the NTB2- ion. 
DTNB
Zn(DPA)x
NTB2-
(DPA)x
TCEPO
TCEP
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the DNTB modifying group from the enzyme through the reduction of its disulfide bond by 
TCEP (see Figure 3.2).  Both steps of the reaction were followed spectrophotometrically at 412 
nm as a consequence of the release of the chromophoric 2-nitro-5-thiobenzoate (NTB2-) anion. 
The chemical modification of VIM-2 was performed in a volume of 180 µL.  Initially, 8 µM 
of VIM-2 in HEPES buffer (50 mM, pH 7.0) was allowed to equilibrate at 25 °C for 1 min.  
Furthermore, the HEPES buffer used was treated with 2.5 g/100 mL of Chelex-100 to minimize 
contamination by trace elements.  The reaction was initiated by the addition of 20 µL of DTNB 
(5 mM in buffer).  The reaction was monitored at a wavelength of 412 nm for 5 min.  After 5 
min, 6.9 µL of DPA (30 mM in buffer) was added to the solution.  Following mixing for 
approximately 30 s, the monitoring of the reaction at 412 nm was resumed.  The final 
concentrations of VIM-2, DTNB and DPA in the assay were 6.97 µM, 483 µM and 1000 µM, 
respectively.  Following the completion of the assay, an Amicon Ultra 0.5 mL centrifugal filter 
(10 kDa MWCO) (Thermo Fisher Scientific Inc., Waltham, Massachusetts, U.S.A.) was used to 
remove any excess DTNB and DPA from the solution.  The successful removal of DTNB was 
assessed using TCEP (absence of the NTB2- ion in the filtrate), while the complete removal of 
DPA was assessed using zinc sulfate and 4-(2-pyridylazo)resorcinol (PAR) at final 
concentrations of 5 µM and 10 µM, respectively.  Following centrifugation, TCEP, at a final 
concentration of 250 µM, was added to remove the remaining modifying agent from the enzyme.  
The reaction was allowed to equilibrate for 5 min at room temperature.  Once the assay was 
complete, an Amicon Ultra 0.5 mL centrifugal filter (10 kDa MWCO) was used to remove the 
excess TCEP and the released NTB2- anion.  The absence of TCEP was assessed using DTNB.  
Following centrifugation, a PAR test was used to assess the zinc content of the enzyme (see 
section 3.12). 
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3.9 Labeling of VIM-2 with the Alexa Fluor Dyes 
The labeling of VIM-2 with the Alexa Fluor dyes was achieved by following a modified version 
of the protocols outlined in the previous section.  The main modification was that the Alexa 
Fluor dyes were used as the cysteine-modifying agent instead of DTNB.  The labeling of VIM-2 
with Alexa Fluor 488 and Alexa Fluor 546 was accomplished in a total volume of 200 µL.  VIM-
2 (40 µM) and TCEP (400 µM) were allowed to incubate at room temperature for 1 min.  
Following the incubation, 800 µM of the desired Alexa Fluor dye was added to the solutions to 
initiate the reaction.  A volume of 22.3 µL of DPA (30 mM in buffer) was then added to the 
solution.  The mixture was incubated at room temperature for 2 h.  Following incubation, a 10-
fold molar excess of β-mercaptoethanol (BME) was added, and the solution was incubated for 
another 30 min at room temperature.   The addition of BME allowed for the quenching of any 
thiol-reactive dye that was still present in the solution, hence ensuring that no reactive species 
were remaining during the purification process.  For VIM-2 labeled with Alexa Fluor 488, the 
final concentrations of VIM-2, TCEP, Alexa Fluor 488 and DPA were 35 µM, 350 µM, 720 µM 
and 3000 µM, respectively.  For VIM-2 labeled with Alexa Fluor 546, the final concentrations of 
VIM-2, TCEP, Alexa Fluor 546 and DPA in the reaction mixture were 35 µM, 340 µM, 720 µM 
and 3000 µM, respectively.  Following the completion of the reaction, an Amicon Ultra 0.5 mL 
centrifugal filter (10 kDa MWCO) was used to remove any excess DPA, BME and Alexa Fluor 
dye from the solution.  The successful removal of DPA was assessed using PAR/Zn2+.  
Following centrifugation, a Pierce 660 nm Protein Assay was conducted to determine protein 
concentration.  The zinc content of labeled VIM-2 was also assessed using PAR (see section 
3.12). 
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Protein concentration following the labeling of VIM-2 with the Alexa Fluor dyes was 
assessed using Thermo Fisher Scientific’s Pierce 660 nm Protein Assay.  This assay represents a 
simple and rapid colorimetric method for the determination of protein concentration that is more 
sensitive than the Coomassie Blue-based Bradford assays.  All assays were performed using the 
96-well microplate procedure (working range 50 to 2,000 µg/mL).  For the assay, BSA standards 
ranging from 50 µg/mL to 600 µg/mL were prepared using a 2 mg/mL stock solution of BSA 
dissolved in PBS buffer (0.1 M, pH 7.2).  A volume of 10 µL of each standard, sample, and a 
reagent blank were added to separate wells of the 96-well microplate along with 150 µL of the 
Pierce 660 nm Protein Assay reagent.  The solutions were then mixed with a pipette, incubated 
for 5 min at room temperature, and the absorbance of the samples was measured at a wavelength 
of 660 nm using an Epoch Microplate Spectrophotometer (BioTek Instruments Inc., Winooski, 
Vermont, U.S.A.).  A BSA standard curve was prepared to determine the concentrations of the 
protein samples. 
3.10 Fluorescence Spectroscopy 
3.10.1 Tryptophan Fluorescence 
Typical tryptophan fluorescence studies were performed in a final volume of 800 μL.  Prior to 
the measurements, the enzyme (1 µM) was pre-incubated at room temperature in 50 mM HEPES 
buffer (pH 7.0 for VIM-2 and pH 7.2 for IMP-1) for 1 min.  After incubation, the fluorescence 
emission spectra were measured from 295 nm to 460 nm.  The excitation wavelength was set to 
295 nm to selectively excite the tryptophan residues present in the proteins.  The spectra were 
measured using an OLIS RSM 1000 DeSa Rapid-Scanning Monochromator Spectrofluorometer 
(OLIS Inc., Bogart, Georgia, U.S.A.) equipped with a 150 W xenon arc lamp.  
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In studies on the interaction of VIM-2 or IMP-1 with inhibitors, spectra were measured 
analogously using a final inhibitor concentration of 5 µM.  Furthermore, 25 µM TCEP was 
occasionally added to the samples to determine the effect of a reducing agent on the interaction 
between VIM-2 and oxidized, disulfide-containing cationic peptides.   
3.10.2 FRET 
Fluorescence resonance energy transfer (FRET) measurements were carried out using two 
fluorescent dyes: Alexa Fluor 488 and Alexa Fluor 546.  For these experiments, Alexa Fluor 488 
was used as the donor while Alexa Fluor 546 acted as the acceptor.  The measurements were 
performed at an excitation wavelength of 492 nm as this wavelength coincides with the 
absorbance maximum of the donor.  For the experiments, changes in donor fluorescence 
emission (fluorescence maximum at 514 nm) and acceptor emission (fluorescence maximum at 
568 nm) were recorded.  Using the OLIS fluorometer, fluorescence emission spectra were 
measured from 500 nm to 600 nm to evaluate the fluorescence emission of both the donor and 
the acceptor. With this procedure, two types of FRET measurements were conducted: protein-
protein FRET and peptide-protein FRET.   
For the protein-protein FRET, measurements were performed using VIM-2 labeled with 
Alexa Fluor 488, and VIM-2 labeled with Alexa Fluor 546 in a 1:1 ratio.  In the samples, both of 
the labeled proteins were measured at a final concentration of 200 nM.  A concentration of 2 µM 
of the unlabeled cysteine-containing (Arg)8 peptide (peptide 14) was used in measurements 
aimed at assessing the influence of cationic peptides on FRET.    
For the protein-peptide FRET, measurements were performed using VIM-2 labeled with 
Alexa Fluor 488, and the cysteine-containing (Arg)8 peptide (peptide 14) labeled with Alexa 
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Fluor 546 in a 1:4 ratio.  In the samples, the final concentrations of the labeled protein and the 
labeled peptide were 100 nM and 400 nM, respectively.   
Following FRET measurements, the distance between the labels was calculated using 
equations 3.5, 3.6, 3.7 and 3.8,  
 R0 = 0.2108 [κ2n-4Φ0J(λ)]1/6 (Equation 3.5) 
 J(λ) = ∫FD(λ)εA(λ)λ4dλ (Equation 3.6) 
 E = R06 / (R06 + r6) (Equation 3.7) 
 r = R0 [(1/E)-1]1/6 (Equation 3.8) 
where R0 is the Förster distance (i.e, energy transfer is 50% at this distance; expressed in Å), κ2 
denotes the orientation factor  (0.476 for rigid donor and acceptor molecules such as the Alexa 
Fluor dyes), n represents the refraction index (1.4 for HEPES buffer), Φ0 is the quantum yield of 
the donor (0.92 for Alexa Fluor 488), J(λ) is the spectral overlap integral between the donor 
emission and the acceptor absorption, FD represents the normalized donor emission spectra (i.e., 
the fluorescence intensity at λmax is set to 1), εA denotes the extinction coefficient of the acceptor 
(120,000 M-1cm1 for Alexa Fluor 546 at 553 nm), λ represents the wavelength (in nm), E is the 
energy transfer efficiency, and r is the distance between the donor and acceptor molecules.  
3.11 Dynamic Light Scattering 
All dynamic light scattering studies were conducted in a final volume of 1 mL, and at a 
temperature of 25 °C using a Zetasizer Nano S90 (Malvern Instruments Inc., Westborough, 
Massachusetts, U.S.A.).  The average hydrodynamic size distribution of the particles in the 
samples was determined using the Zetasizer software (Malvern Instruments Inc., Westborough, 
Massachusetts, U.S.A.).  As controls, at the beginning of each experiment, HEPES buffer (20 
mM, pH 7.4), VIM-2 and/or the (Arg)8 core peptide [Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH; 
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peptide 7 in Table 3.2] were measured.  For the first experiment, 8 µM VIM-2 and 80 µM of the 
peptide were incubated with 20 mM HEPES buffer (pH 7.4) for 1 min at room temperature.  A 
second experiment was performed to further study the interaction between VIM-2 and the 
peptide by combining 8 µM VIM-2 with increasing concentrations of the peptide in 20 mM 
HEPES buffer to obtain a titration curve.  The final concentrations of the (Arg)8 core peptide in 
the assays were 1.6 µM, 4 µM, 8 µM, 16 µM, 40 µM and 80 µM.  The initial concentration of 
VIM-2 (8 µM) slightly decreased upon the addition of the increasing concentrations of the 
peptide to the sample, but this decrease in concentration was negligible due to the high 
concentration of the peptide stock solution used for the dilutions.  
3.12 Determination of Metal Content 
PAR [4-(2-pyridylazo)resorcinol] is a chromogenic chelator frequently used to detect metals 
present in protein samples [131].  Therefore, a PAR test was used to assess the zinc content of 
VIM-2.  The PAR assay was performed in a 96-well microplate.  For a typical assay, 4 M 
GdnHCl was combined with 2 µM to 5 µM of the protein in 50 mM HEPES buffer (pH 7.4).  
GdnHCl was used to denature/unfold the protein to release the zinc ion from the protein.  
Afterwards, 50 µM of PAR was added to the solution to initiate its complexation to the Zn2+ 
ions.  The solution was then incubated for 15 min.  Following incubation, the absorbance of the 
samples was measured at 500 nm using the Epoch Microplate Spectrophotometer.  Zinc 
standards were also prepared in the range from 1 µM to 10 µM, and assayed under analogous 
conditions.  A standard curve was prepared to determine the concentration of zinc in the protein 
samples. 
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Chapter 4: Results 
4.1 Inhibition of VIM-2 by Cationic Peptides 
Previous (unpublished) studies have shown that S-pNA (peptide 1 in Table 4.1), a peptidic lethal 
factor substrate, has the ability to inhibit VIM-2.  This observation is unusual due to the 
stereochemistry of β-lactams imitating the D-Ala-D-Ala configuration rather than the L, L 
configuration found in S-pNA.  Hence, a more thorough study of the effect of cationic peptides 
on MBLs was initiated.  The interaction between VIM-2 and cationic peptides was studied by 
monitoring the rate of the enzyme-mediated hydrolysis of nitrocefin as a function of the 
concentration of the inhibitors.  Among the cationic peptides listed in Table 4.1, peptides that 
differed in their C-terminal moieties were analyzed.  The results indicated that the inhibition of 
VIM-2 was relatively independent of the nature of the C-terminal moiety (para-nitroanilide, 
hydroxamate or a free carboxylic acid; see peptides 1, 3 and 4 in Table 4.1).  Furthermore, Ala-
Pro-pNA, which contains the C-terminal pNA group, but is devoid of cationic residues, was 
shown to be a very poor inhibitor of VIM-2 with an IC50 value of 1155 µM.  Replacement of the 
C-terminal arginine residue of S-pNA (peptide 1) with a proline residue led to only slightly 
lower inhibitory potency (compare peptides 1 and 2 in Table 4.1).  
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Table 4.1: IC50 values for the inhibition of VIM-2 by various cationic peptides.  Inhibition was 
assessed at room temperature using 6 nM of VIM-2 and 100 µM of nitrocefin.  The values 
represent the mean (± 1 s.d.) of three independent experiments. 
Peptide IC50 (µM) 
1 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-pNA 0.096 ± 0.002 
2 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Pro-pNA 0.179 ± 0.004 
3 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-NHOH 0.329 ± 0.026 
4 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 0.174 ± 0.014 
5 Ac-Gly-Tyr-βAla-(Arg)7-Val-Leu-Arg-OH 0.317 ± 0.037 
6 Ac-Gly-Tyr-βAla-(Arg)6-Val-Leu-Arg-OH 2.484 ± 0.988 
7 Ac-Gly-Tyr-βAla-(Arg)5-Val-Leu-Arg-OH > 500 
8 Ac-Gly-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH > 500 
9 Ac-Nle-(Lys)4-Val-Leu-Pro-pNA > 500 
10 Ac-Nle-(Arg)4-Val-Leu-Arg-OH 27 ± 4 
11 Poly-arginine (5 to 15 kDa) 0.017 ± 0.004 
12 Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 0.826 ± 0.150 
13 
Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 
           │ 
Ac-Cys-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH 
0.534 ± 0.063 
14 Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 0.118 ± 0.021 
15 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
           │ 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
0.013 ± 0.001 
16 Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Cys-OH 0.107 ± 0.002 
Since the previous results indicated that positively charged residues in the peptides were 
responsible for the inhibition of VIM-2, a variety of peptides containing different numbers of 
core arginine residues were evaluated for their inhibitory potency.  As shown in Table 4.1, the 
successive truncation of the (Arg)8 core of the peptides to an (Arg)4 core led to a dramatic 
decrease in inhibition with IC50 values increasing from 0.174 µM to over 500 µM (see peptides 4 
to 8 in Table 4.1).  The largest decrease in inhibition occurred following the shortening of the 
(Arg)6 core to an (Arg)5 core with IC50 values increasing from 2.484 µM to 500 µM (see peptides 
6 and 7 in Table 4.1).  Since these results indicated that the positively charged core residues of 
the peptides were important for the inhibition of VIM-2, a peptide that contained lysine residues 
instead of arginine residues was evaluated (peptide 9).  This peptide was found to be a poor 
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inhibitor of VIM-2 (IC50 > 500 µM; see Table 4.1).  However, the replacement of the C-terminal 
proline and the (Lys)4 motif of the peptide with arginine residues caused the inhibition to 
significantly increase from over 500 µM to 27 µM (see peptides 9 and 10 in Table 4.1).  These 
results demonstrate that incorporation of arginine residues into the peptides leads to more potent 
inhibition than that observed with lysine residues.  Indeed, a peptide containing only arginine 
residues was shown to be a very potent inhibitor of VIM-2 with an IC50 value of 17 nM (see 
peptide 11 in Table 4.1).  Furthermore, when comparing peptides 9 and 10, which contain the 
same core motif and C-terminal residues, it was observed that just the slight difference in their 
N-terminal residues caused a dramatic difference in inhibition with the IC50 values decreasing 
from over 500 µM for peptide 8 (Ac-Gly-Tyr-βAla) to 27 µM for peptide 10 (Ac-Nle).  To 
further confirm that changes in the N-terminus affect inhibition, peptides that contained an N-
terminal cysteine residue instead of a glycine residue were evaluated.  For the (Arg)4 core 
peptide, this substitution caused a significant increase in the inhibitory potency (compare 
peptides 8 and 12 in Table 4.1).  In addition, oxidation of peptide 12 to the disulfide led to a 
further increase in inhibition as shown by its IC50 value of 534 nM (see peptide 13 in Table 4.1).  
For the (Arg)8 core peptide, the substitution of the N-terminal glycine residue with a cysteine 
residue only minimally increased the inhibitory potency of the peptide (see peptides 4 and 14 in 
Table 4.1).  In addition, a peptide containing an N-terminal and a C-terminal cysteine residue 
exhibited a slight increase in its inhibitory potency in comparison to its cysteine-devoid 
equivalent (compare peptides 4 and 16 in Table 4.1).  Interestingly, oxidation of the cysteine-
containing (Arg)8 core peptide was shown to cause a significant increase in inhibition as shown 
by its IC50 value of 13 nM (see peptide 15 in Table 4.1).  Indeed, among the peptides 
investigated in this study, peptide 15 was found to be the most potent inhibitor of VIM-2.  
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4.2 β-Lactam Substrates 
In order to investigate whether the inhibition of VIM-2 by cationic peptides is substrate-
dependent, a variety of β-lactam substrates other than nitrocefin including a variety of 
cephalosporins, benzylpenicillin and imipenem (a carbapenem) were employed in the assessment 
of the inhibitory potency of S-pNA (peptide 1 in Table 4.1).  As shown in Table 4.2, the 
inhibitory potency of S-pNA decreased significantly upon the substitution of nitrocefin with 
other substrates.  Nonetheless, moderate inhibition of VIM-2 by S-pNA was observed with all of 
the β-lactam substrates tested.  The degree of inhibition appeared to be mainly dependent on the 
nature of the R2 group of the substrates.  For instance, in the case of nitrocefin, cephaloridine and 
cephalothin, which share the same R1 moiety (but not the same R2 substituent), the inhibitory 
potency of S-pNA varied significantly with activities ranging from 13% to 84% (see Table 4.2).  
Similar results were obtained when comparing cefoxitin and cephalothin since these two 
substrates demonstrated significantly different activities (see Table 4.2).  Although cefoxitin and 
cephalothin share the same R1 moiety and possess similar R2 groups, cefoxitin contains a 
methoxy group at the α-carbon of the β-lactam ring.  Another difference between both of these 
substrates is that the inhibition with cephalothin was assessed using 10 µM S-pNA while that of 
cefoxitin was assessed using only 1 µM S-pNA.  Therefore, even at a 10-fold decrease in 
concentration, S-pNA demonstrated a higher degree of inhibition with cefoxitin as a substrate.  
On the other hand, in the case of cephalosporin C and cephalothin, which share the same R2 
moiety, but vary in their R1 substituent, the degree on inhibition was similar with activities of 
67% and 84%, respectively (see Table 4.2).  A penicillin and a carbapenem were also used as 
substrates.  The results indicated that S-pNA-mediated inhibition with these two substrates gave 
similar residual activities (see Table 4.2).    
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Table 4.2: The dependence of the inhibition of VIM-2 by S-pNA on the chosen substrate.  
Inhibition was assessed in HEPES buffer (50 mM, pH 7.0) at room temperature using 6 nM 
VIM-2 and 10 µM S-pNA (except for assays in the presence of nitrocefin and cefoxitin where it 
was 1 µM).  Benzylpenicillin and imipenem were used at final concentrations of 45 and 350 µM, 
respectively.  All other substrates were measured at a final concentration of 100 µM.  These 
substrate concentrations were employed as they were approximately five times larger than the 
Michaelis constant of the substrates.  The values represent the mean (± 1 s.d.) of three 
independent experiments. 
β-Lactam 
substrate Structure Activity (%) 
 
Nitrocefin 
(Cephalosporin) 
 
 
13 ± 1 
Cephaloridine 
(Cephalosporin) 
 
30 ± 2 
Cephalothin 
(Cephalosporin) 
 
84 ± 5 
Cephalosporin C 
(Cephalosporin) 
 
67 ± 9 
Cefoxitin 
(Cephamycin) 
 
30 ± 3 
 
Benzylpenicillin 
(Penicillin) 
 
 
45 ± 1 
 
Imipenem 
(Carbapenem) 
 
 
 
38 ± 3 
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Since nitrocefin was the substrate with which the lowest activity, and hence highest degree of 
inhibition by S-pNA was observed, two substrates structurally similar to nitrocefin (UW-57 and 
UW-58) were assayed.  When comparing nitrocefin, UW-57 and UW-58, which share the same 
R1 moiety, but differ in their R2 groups, the degree of inhibition was determined to be fairly 
similar ranging from 13% to 22% (see Table 4.3).  In view of these results, the IC50 values of all 
three substrates were measured.  As shown in Table 4.3, the IC50 values of the UW substrates 
were found to be five to six times larger than that of nitrocefin.   
Table 4.3:  Inhibition of VIM-2 by S-pNA using nitrocefin and nitrocefin-like substrates.  
Inhibition was assessed in HEPES buffer (50 mM, pH 7.0) at room temperature using 6 nM 
VIM-2 and 100 µM substrate.  The percentage of activity was determined using 1 µM of S-pNA.  
The concentration of S-pNA varied in the activity assays for the determination of the IC50 values.  
The values represent the mean (± 1 s.d.) of three independent experiments. 
β-Lactam 
substrate Structure Activity (%) IC50 (nM)
 
Nitrocefin 
 
13 ± 1 96 ± 2 
UW-57 
 
22 ± 4 523 ± 87 
UW-58 
 
18 ± 1 575 ± 40 
4.3 The Effect of Salts on the Inhibition of VIM-2 by the Cationic Peptides 
In view of the ionic nature of the peptide inhibitors, the effect of salts on the inhibition of VIM-2 
by S-pNA was explored.  As shown in Table 4.4, all salts had approximately the same ionic 
strength, and showed similar activities in the absence of inhibitor.  The addition of salt to the 
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inhibition assays greatly increased the level of residual activity (see Table 4.4).  Therefore, all 
salts were capable of reducing S-pNA-mediated inhibition.  Furthermore, the results illustrate 
that the relief of inhibition was particularly strong with salts containing divalent anions such as 
Na2SO4 and MgSO4 which demonstrated residual activities of 76% and 78%, respectively.  
Na2WO4 displayed the greatest relief of inhibition with 93% of residual activity being observed.  
Table 4.4: Dependence of the inhibition of VIM-2-mediated nitrocefin hydrolysis by S-pNA on 
the chosen salt.  Inhibition was assessed in HEPES buffer (50 mM, pH 7.0) at room temperature 
using 6 nM VIM-2, 100 µM nitrocefin and 1 µM S-pNA.  The values represent the mean (± 1 
s.d.) of three independent experiments. 
Salt Concentration (mM) Ionic Strength 
Activity (%) 
- S-pNA + S-pNA1 
None —  — 100 13 (± 1) 
NaBr 100 0.100 77 (± 9) 68 (± 8) 
NaCl 100 0.100 115 (± 10) 37 (± 3) 
MgCl2 25 0.075 94 (± 13) 46 (± 5) 
CaCl2 25 0.075 74 (± 12) 55 (± 2) 
Na2SO4 25 0.075 98 (± 14) 76 (± 6) 
MgSO4 25 0.100 111 (± 8) 78 (± 7) 
Na2WO4 25 0.075 82 (± 7) 93 (± 5) 
1 Activities are expressed relative to those recorded in the absence of S-pNA. 
4.4 Enzyme Kinetics of VIM-2 and the Cationic Peptides   
The mode of inhibition of VIM-2 by S-pNA was evaluated using nitrocefin as a substrate.  The 
inhibition of VIM-2 by S-pNA revealed a complex and unusual mode of inhibition.  A 
Lineweaver-Burk plot was obtained by plotting the reciprocal velocity against the reciprocal 
nitrocefin concentration demonstrating that the lines crossed in the negative (third) quadrant (see 
Figure 4.1).  For competitive inhibition, the lines intersect on the y axis while for pure non-
competitive inhibition, the lines intersect on the x axis.   
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Figure 4.1: Lineweaver-Burk and Michaelis-Menten (inset) plots of VIM-2 inhibition by S-
pNA.  The lines depict the best fit of the data to equation 3.1 describing the formation of an 
enzyme-product-inhibitor ternary complex as outlined in section 3.3.  VIM-2 was used at a final 
concentration of 6 nM.   
Although the data demonstrated an unusual type of inhibition, the data could be fit reasonably 
well to two equations describing two distinct mechanisms.  The first mechanism involved an 
enzyme-product-inhibitor ternary complex while the second mechanism was hyperbolic (partial) 
mixed-type inhibition.  As shown in Figure 4.2, the enzyme-product-inhibitor ternary complex 
mechanism describes a type of inhibition where the product and the inhibitor bind the enzyme at 
two different sites.  This produces three different enzyme-containing complexes called EI, EP 
and EPI.  On the other hand, hyperbolic (partial) mixed-type inhibition illustrates a type of 
mechanism where the substrate and the inhibitor bind the enzyme at two different sites.  This 
also produces three different enzyme-containing complexes (EI, ES and EIS).  In the case of 
hyperbolic (partial) mixed-type inhibition, the value of α is between 0 and 1, while β is < 1, but 
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the fits where obtained with β equal to 0.  An α value between 0 and 1 causes the lines (in the 
Lineweaver-Burk plot) to intersect in the third quadrant with the inhibitor binding more tightly to 
the enzyme-substrate complex than to the free enzyme [129].  The main difference between both 
mechanisms lies in the production of the EPI and EIS complexes.    
                             
Figure 4.2: Schemes for the enzyme-product-inhibitor ternary complex mechanism (A) and 
hyperbolic mixed-type inhibition (B).  E denotes the free enzyme, S represents the substrate, I is 
the inhibitor, P is the product, EI symbolizes the enzyme-inhibitor complex, ES is the enzyme-
substrate complex, EIS represents the enzyme-substrate-inhibitor complex, EP denotes the 
enzyme-product complex, and EPI is the enzyme-product-inhibitor complex.  Schemes adapted 
from references [128, 129]. 
It is important to note that both mechanisms cannot be distinguished on basis of the virtually 
identical velocity equations and Lineweaver-Burk expressions (see section 3.3).  Indeed, the only 
major difference is that Ki′app is replaced by αKi in hyperbolic (partial) mixed-type inhibition (see 
equations 3.2 and 3.4).  Hence, it is not surprising that the Vmax, KM, Ki and kcat values obtained 
by fitting the data to both models were identical, while the Ki′app value is the product of α and Ki 
(i.e., Ki′app = α × Ki) (see Table 4.5).  In addition, the KM and the kcat values for VIM-2 and 
nitrocefin in the literature are 18 μM and 770 s-1, respectively [126].  Hence, the experimental 
KM values that were determined for both mechanisms were identical to the literature value, while 
the values for kcat were different by a factor of ~ 4.   
 
 
E + S ES EP E + P
EPIEI
 + +
I I
KM k2 k3
Ki Ki'
E + S ES E + P
EISEI + S
 + +
I I
KM kcat
Ki αKi
EI + P
βkcatαKM
A B 
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Table 4.5: Kinetic parameters for both the mechanism involving the formation of an enzyme-
product-inhibitor ternary complex as well as the hyperbolic (partial) mixed-type inhibition.  Vmax 
is the maximum velocity, KM is the Michaelis constant, Ki is the inhibition constant, Ki′app is 
(k3/k2)Ki′ and kcat is the catalytic constant.    
Kinetic parameters Enzyme-Product-Inhibitor Ternary Complex 
Hyperbolic (partial) 
mixed-type inhibition 
Vmax 1.03 (± 0.04) Δ abs/min 1.03 (± 0.04) Δ abs/min 
KM 17.63 (± 2.15) µM 17.63 (± 2.23) µM 
Ki 1.17 (± 0.79) µM 1.17 (± 0.83) µM 
Ki′app 0.36 (± 0.05) µM ― 
α ― 0.31 (± 0.26) 
β ―  0 
kcat 178 (± 7) s-1 178 (± 7) s-1 
4.5 Stopped-flow Analysis of VIM-2 and the Cationic Peptides   
Since the enzyme kinetics of the reaction between VIM-2 and S-pNA could be fit to two possible 
inhibition mechanisms, rapid scanning stopped-flow experiments were performed to determine 
the type of inhibition [enzyme-product-inhibitor ternary complex vs. hyperbolic (partial) mixed-
type inhibition].  The rapid-scanning studies were conducted under double-turnover conditions 
by rapidly mixing 10 µM VIM-2 with 20 µM nitrocefin.  The reaction was monitored over the 
wavelength range of 350 nm to 575 nm for 1.2 s.  The spectra showed two prominent peaks at 
390 nm and 490 nm (see Figure 4.3).  The peak at 390 nm was due to the absorbance of 
nitrocefin, and disappeared as the experiment progressed due to substrate turnover.  The peak at 
490 nm was due to the absorbance of the product (hydrolyzed nitrocefin).  The product was 
completely formed (> 99%) after approximately 400 ms.  Furthermore, since previous studies 
conducted on similar MBLs such as NDM-1 demonstrated a peak at 665 nm, the stopped-flow 
experiments were repeated from 475 nm to 700 nm.  The peak at 665 nm corresponds to a ring-
opened anionic intermediate which is thought to be stabilized by the active site zinc ions [132].  
As expected, the spectra demonstrated the appearance of the hydrolyzed nitrocefin at 490 nm as 
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the experiment progressed.  However, there was no spectral evidence of the peak of the 
nitrocefin intermediate at 665 nm (data not shown). 
 
Figure 4.3: Time course for the VIM-2-catalyzed hydrolysis of nitrocefin.  Nitrocefin hydrolysis 
was measured in HEPES buffer (50 mM, pH 7.0) at a temperature of 20 °C.  VIM-2 and 
nitrocefin were rapidly mixed using a U.S.A. stopped-flow device to achieve final concentrations 
of 10 µM and 20 µM, respectively.  The time course demonstrates the depletion of nitrocefin 
through the disappearance of the peak at 390 nm, and the formation of hydrolyzed nitrocefin 
through the appearance of the peak at 490 nm.  The reaction was complete in ~ 400 ms.  
Single-wavelength stopped-flow analyses were conducted for the substrate and the product 
which absorbed at 390 nm and 490 nm, respectively.  The absorbance data obtained at these two 
wavelengths were converted into concentrations, and plotted as a function of time (see Figure 
4.4).  Data sets were acquired from the hydrolysis of 20 µM nitrocefin by 10 µM VIM-2 in the 
absence and in the presence of 10 µM of the (Arg)7 core peptide (peptide 5).  In the case of 
supplementation with the (Arg)7 core peptide, two data sets were recorded; one where the 
peptide was pre-exposed to VIM-2 prior to the start of the reaction, and the other where the 
peptide was pre-exposed to nitrocefin.  The results demonstrated that in the presence of the 
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(Arg)7 core peptide, a decrease in the rate of hydrolysis was observed.  As seen in Figure 4.4, the 
rate reduction was particularly prominent following the first turnover.  During the first turnover, 
the curves demonstrate fairly similar hydrolysis rates.  However, once the nitrocefin 
concentration reached 10 µM (i.e., after the first turnover), the curves started to deviate.  The 
results also illustrate that the rate reduction depended on whether the (Arg)7 core peptide was 
pre-exposed to nitrocefin or to VIM-2.  As shown in Figure 4.4, the rate of nitrocefin hydrolysis 
by VIM-2 upon the pre-exposure of the (Arg)7 core peptide to nitrocefin was slower than that of 
the pre-exposure of the (Arg)7 core peptide to VIM-2.    
 
Figure 4.4: Time course of nitrocefin hydrolysis by VIM-2 in the absence and presence of the 
(Arg)7 core peptide (10 µM; peptide 5).  Nitrocefin hydrolysis was measured at a temperature of 
20 °C in HEPES buffer (50 mM, pH 7.0).  The time course demonstrates substrate and product 
concentrations which were measured at 390 nm and 490 nm, respectively.  VIM-2 and nitrocefin 
were rapidly mixed to achieve final concentrations of 10 µM and 20 µM, respectively (red).  The 
blue and green traces represent the progress of nitrocefin hydrolysis following the pre-exposure 
of the (Arg)7 core peptide to VIM-2 and nitrocefin, respectively.   
The rapid-scanning stopped-flow experiments were also performed under single-turnover 
conditions by rapidly mixing 20 µM VIM-2 with 20 µM nitrocefin.  Similar to the previous 
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stopped-flow studies, the spectra demonstrated prominent peaks including a substrate peak at 
390 nm that decreased over time, and a product peak at 490 nm that emerged over time (see 
Figure 4.5A).  When poly-arginine (50 µM; peptide 11) was used as an inhibitor and pre-exposed 
to nitrocefin, the substrate peak at 390 nm appeared very similar to that of the reaction between 
VIM-2 and nitrocefin conducted in the absence of the inhibitor (see t = 0 s trace in Figure 4.5B).  
However, the emergence of the peak at 490 nm was delayed in comparison to that of the reaction 
between VIM-2 and nitrocefin in the absence of poly-arginine, a feature indicative of poly-
arginine inhibiting nitrocefin turnover.  Furthermore, as the reaction progressed both substrate 
and product peaks became distorted with higher than expected absorption being observed 
especially at shorter wavelengths (see Figure 4.5B).  This result is consistent with the emergence 
of scattering during the VIM-2-mediated hydrolysis of nitrocefin in the presence of poly-
arginine.  When poly-arginine was pre-exposed to VIM-2, the substrate peak at 390 nm was 
considerably different from those of the two previous reactions (see Figure 4.5C).  The 
absorbance of the peak at t = 0 s was considerably higher, presumably due to scattering.  
However, the product peak at 490 nm was fairly similar to that noted for poly-arginine pre-
exposed to nitrocefin (compare Figure 4.5B and Figure 4.5C).   
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Figure 4.5: Time courses for nitrocefin hydrolysis by VIM-2 in the absence and the presence of 
poly-arginine.  a) Time course for the VIM-2 catalyzed hydrolysis of nitrocefin in the absence of 
inhibitor.  b) Time course for nitrocefin hydrolysis by VIM-2 with poly-arginine pre-exposed to 
the nitrocefin.  c) Time course for the VIM-2 catalyzed hydrolysis of nitrocefin with poly-
arginine pre-exposed to VIM-2.  For all the experiments, nitrocefin hydrolysis was measured at a 
temperature of 20 °C in HEPES buffer (50 mM, pH 7.0).  VIM-2 and nitrocefin were rapidly 
mixed to achieve final concentrations of 20 µM in the absence and the presence of 50 µM poly-
arginine.  The time courses demonstrate the depletion of nitrocefin through the disappearance of 
the peak at 390 nm and the formation of hydrolyzed nitrocefin through the appearance of the 
peak at 490 nm.  The insets illustrate changes in the absorbance at 390 nm (lighter trace) and 490 
nm (darker trace) during the reaction. 
In addition, for all three reactions, single-wavelength stopped-flow analyses were performed 
for the substrate and the product which absorbed at 390 nm and 490 nm, respectively (see insets 
in Figure 4.5).  The results demonstrated that in the presence of poly-arginine, a decrease in the 
rate of hydrolysis was observed (see insets in Figure 4.5).  The results also indicated that the rate 
reduction was fairly similar regardless of poly-arginine being pre-exposed to nitrocefin or to 
VIM-2.  When the data was fit to an A  B model (i.e., nitrocefin  hydrolyzed nitrocefin), the 
rate constant for the hydrolysis of nitrocefin by VIM-2 in the absence of inhibitor was 15.1 (± 
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1.4) s-1.  Using the same model, the rate constant for the hydrolysis of nitrocefin by VIM-2 was 
1.42 (± 0.14) s-1, and thus one order of magnitude smaller, when poly-arginine was pre-exposed 
to VIM-2 prior to the reaction.  The data from the hydrolysis of nitrocefin by VIM-2 when poly-
arginine was pre-exposed to nitrocefin could not be fit to any model in view of the hydrolysis of 
nitrocefin and protein aggregation occurring at the same time during the stopped-flow reaction.   
4.6 Fluorescence Studies on VIM-2 and the Cationic Peptides 
In order to study the interaction between VIM-2 and the cationic peptides, intrinsic tryptophan 
fluorescence studies were conducted.  If the interaction between VIM-2 and the cationic peptides 
were to induce conformational changes within the protein, alterations in the fluorescence 
emission spectrum of the protein (shift in λmax or change in fluorescence intensity) should be 
observable.  Furthermore, fluorescence spectroscopy is a sensitive technique for identifying light 
scattering, a phenomenon observed in the previous single-turnover stopped-flow study.  The 
results revealed that the fluorescence emission spectrum of VIM-2 shows one distinct peak at a 
wavelength of 333 nm whereas that of the (Arg)7 core peptide (peptide 5 in Table 4.1) was 
essentially featureless (see Figure 4.6).  However, the fluorescence spectrum of VIM-2 in the 
presence of the (Arg)7 core peptide, although displaying a virtually identical λmax value, and 
similar fluorescence intensities, showed a dramatic increase in fluorescence intensity at 295 nm.  
This prominent increase in fluorescence intensity (at 295 nm; i.e., the excitation wavelength) is 
likely to be caused by light scattering due to aggregation.  
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Figure 4.6: Tryptophan fluorescence emission spectra of VIM-2 and the (Arg)7 core peptide 
(peptide 5).  The spectra were measured in HEPES buffer (50 mM, pH 7.0) at room temperature 
using an excitation wavelength of 295 nm.  VIM-2 and the (Arg)7 core peptide were tested at 
final concentrations of 1 µM and 5 µM, respectively.  Spectrum of VIM-2 (blue), the (Arg)7 core 
peptide (red), and VIM-2 + (Arg)7 core peptide (green and purple).  The solid lines represent 
experimental data while the dashed line symbolizes the additive spectrum obtained through the 
addition of the blue and the red traces.  ∆FI denotes the difference in the fluorescence intensity at 
295 nm between the green and the purple traces.  The spectra represent the average of three 
independent experiments.   
To analyze the level of scattering at 295 nm, the fluorescence intensity at 295 nm of the 
additive spectrum was subtracted from that of the experimental spectrum.  Using the (Arg)7 
peptide as an example, if there was no interaction between VIM-2 and the peptide, the 
fluorescence emission spectrum of the mixture should equal the sum of the individual spectra of 
VIM-2 and the (Arg)7 core peptide (see Figure 4.6).  As outlined above, however, the large 
discrepancy between the additive spectrum and that observed experimentally (ΔFI; Figure 4.6) is 
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indicative of peptide-induced VIM-2 aggregation.  Hence, the propensity of other cationic 
peptides to cause VIM-2 aggregation was assessed based on the ΔFI value.   
 
Figure 4.7: Difference of fluorescence intensity at 295 nm for the emission spectra of VIM-2 in 
the presence of various cationic peptides.  The spectra were measured in HEPES buffer (50 mM, 
pH 7.0) at room temperature using an excitation wavelength of 295 nm.  VIM-2 and the cationic 
peptides were used at final concentrations of 1 µM and 5 µM, respectively.  The purple squares 
correspond to the peptides that contained a cysteine residue in their N-terminus instead of a 
glycine residue (peptides 12, 14 and 15).  The 16 arginine peptide denotes the (Arg8Cys)2 core 
peptide (peptide 15) while the >28 core peptide represents poly-arginine (peptide 11).  
∆Fluorescence intensity denotes the difference in fluorescence intensity between the 
experimental and additive spectra.  Data shown represent the mean of three independent 
experiments.  The error bars symbolize the mean (± 1 s.d.) of the three independent experiments. 
As shown in Figure 4.7, the difference of the fluorescence intensity at 295 nm increased with 
the number of arginine residues in the peptides.  This observation corresponds well with the 
inhibitory potency of these peptides obtained in previous experiments (see Table 4.1).  For 
instance, the (Arg)4 and the (Arg)5 core peptides (peptides 8 and 7, respectively) were poor VIM-
2 inhibitors, and they did not display an  appreciable value for ∆FI.  Furthermore, an increase in 
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the number of core arginine residues to six (peptide 6) not only resulted in an increase in 
inhibitory potency, but also in the first observable increase in ∆FI, and hence, scattering.  Finally, 
poly-arginine (peptide 11) and the disulfide-containing (Arg)8 core peptide [(Arg8Cys)2; peptide 
15] were not only the most potent inhibitors of VIM-2, but they also demonstrated the highest 
∆FI values. 
4.7 UV-Vis Wave Scans with VIM-2 and the Cationic Peptides 
Since the fluorescence studies suggested aggregation of VIM-2 in the presence of cationic 
peptides, UV-Vis wave scans were performed to confirm the existence of such aggregates.  As in 
the previous fluorescence studies, aggregation of VIM-2 should be observable through an 
increase of absorbance in the short wavelength limb of the protein spectrum.  As shown in Figure 
4.8, the absorption spectrum of VIM-2 revealed a distinct peak at a wavelength of 280 nm.  The 
UV-Vis wave scans were also conducted with inhibitors.  The inhibitors used were the (Arg)5 
and the (Arg8Cys)2 core peptides (peptides 7 and 15, respectively).  The results show that the 
absorption spectra of VIM-2 with these two peptides exhibited one distinct peak at a wavelength 
of approximately 275 nm (see Figure 4.8).   
 
 
76 
 
 
Figure 4.8: Absorption spectra of VIM-2 in the presence and absence of the (Arg)5 and 
(Arg8Cys)2 core peptides.  The spectra were measured in HEPES buffer (50 mM, pH 7.0) at 
room temperature.  VIM-2 and the cationic peptides were used at final concentrations of 1 µM 
and 5 µM, respectively.  Spectrum of VIM-2 (black); the (Arg)5 core peptide (blue); VIM-2 + 
(Arg)5 core peptide (red and green), and VIM-2 + (Arg8Cys)2 core peptide (purple).  The solid 
lines indicate experimental data while the dashed lines denote the additive spectra obtained 
through the addition of the individual spectra of VIM-2 and the cationic peptides.  The spectra 
represent the average of three independent experiments.   
Similar to the fluorescence studies, the scattering at 250 nm in the absorption spectra was 
evaluated through the comparison of the experimental and additive spectra.  Using the (Arg)5 
core peptide as an example, if there was no interaction between VIM-2 and the (Arg)5 core 
peptide, the experimental spectrum should match that of the individual spectra of VIM-2 and the 
(Arg)5 core peptide added together.  Actual experimental data demonstrated that the interaction 
between VIM-2 and the (Arg)5 core peptide was minimal since the experimental spectrum was 
nearly identical to the additive spectrum.  However, using the (Arg8Cys)2 core peptide as an 
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example, there was an interaction between VIM-2 and this peptide since the experimental 
spectrum did not coincide with that of the additive spectrum for this sample.  In comparison to 
the additive spectrum, the experimental spectrum demonstrated no shift in λmax, but a 
considerable amount of scattering in the entire spectrum, especially at 250 nm (see Figure 4.8).  
Therefore, the difference in absorbance at 250 nm was evaluated for a variety of peptides by 
subtracting the absorbance at 250 nm of the additive spectra from that of the experimental 
spectra.  The results demonstrate that the difference in absorbance at 250 nm, and thus the degree 
of scattering, increased with the number of arginine residues in the peptides (see Table 4.6).  
Therefore, these results correlate well with the inhibitory potency of these peptides, and with 
those observed in the previous fluorescence studies (see Table 4.1 and Figure 4.7).   
Table 4.6: Difference in absorbance at 250 nm for the spectra of VIM-2 with various cationic 
peptides.  The spectra were measured in HEPES buffer (50 mM, pH 7.0) at room temperature.  
VIM-2 and the cationic peptides were used at final concentrations of 1 µM and 5 µM, 
respectively.  ∆Absorbance denotes the difference in absorbance at 250 nm between the 
experimental and additive spectra.  The values represent the mean (± 1 s.d.) of three independent 
experiments.   
Peptide # in Table 4.1  Number of Arg in core ∆ Absorbance at 250 nm 
7 5 -0.005 (± 0.002) 
4 8 0.008 (± 0.001) 
14 8 0.038 (± 0.001) 
15 16 0.028 (± 0.004) 
11 > 28 0.126 (± 0.035) 
4.8 Native PAGE of VIM-2 in the Presence of Cationic Peptides 
Since the fluorescence studies as well as the UV-Vis wave scans indicated the occurence of 
aggregation between VIM-2 and the cationic peptides, native polyacrylamide gel electrophoresis 
(PAGE) was performed to initially estimate the size of the aggregates (e.g., dimer, tetramer, etc.)  
As seen in Figure 4.9, the VIM-2 preparation was found to be homogeneous as evidenced by the 
appearance of one distinct band in the gel.  However, for a sample comprised of 10 µM VIM-2, 
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and 100 µM of the (Arg)5 core peptide (peptide 7) or 100 µM of the (Arg)8 core peptide (peptide 
4), the same band was found to be very weak (see Figure 4.9).  To confirm that the reduction in 
the intensity of the bands was truly caused by the interaction of the cationic peptides with VIM-
2, a BSA sample in the absence and the presence of the (Arg)8 core peptide was run as a control, 
revealing two prominent bands.  These bands correspond to the monomeric and the dimeric 
forms of BSA which have molecular masses of 66 kDa and 132 kDa, respectively (see Figure 
4.9).  More importantly, the bands of the BSA/(Arg)8 peptide sample did not diminish in 
intensity in comparison to the bands of the sample containing only BSA.  Therefore, these results 
suggest that the diminished intensity of the VIM-2 bands was caused by the interaction between 
VIM-2 and the cationic peptide.  
 
Figure 4.9: Native PAGE of VIM-2 in the absence and the presence of the (Arg)5 and the (Arg)8 
core peptides.  All experiments were conducted with 1 mg/ mL of BSA, 10 µM of VIM-2 and/or 
100 µM of the (Arg)5 or (Arg)8 core peptides.  Lane 1, BSA; lane 2, VIM-2; lane 3, VIM-2 + 
(Arg)5 core peptide; lane 4, VIM-2 + (Arg)8 core peptide; lane 5, BSA + the (Arg)8 core peptide.     
1          2          3         4          5 
66 kDa 
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Densitometry was employed to quantify the intensity of the bands of the samples containing 
VIM-2.  The densitometry results confirmed that the band for the sample containing only VIM-2 
was more intense than the bands of the samples containing VIM-2 and the cationic peptides.  The 
sample consisting of VIM-2 and the (Arg)5 core peptide had a band intensity of 14.3% relative to 
that of the sample containing only VIM-2, whereas the sample comprised of VIM-2 and the 
(Arg)8 core peptide had an intensity of 1.7%.  Interestingly, no bands of higher molecular mass 
could be detected in the gel to justify the decreased intensity of the VIM-2 bands or to 
demonstrate the presence of distinct aggregates in the samples.        
4.9 Paper Electrophoresis of VIM-2 in the Presence of Cationic Peptides 
Since no distinct aggregates of VIM-2 and the cationic peptides could be detected by native 
PAGE, paper electrophoresis was conducted to determine if the aggregates traveled in the 
opposite direction (i.e., towards the cathode) during the experiment (due to the aggregates 
potentially being highly positively charged).  As shown in Figure 4.10, a sample containing 10 
µM VIM-2 revealed a circular shape on the TLC paper which migrated towards the anode.  A 
sample consisting of 10 µM VIM-2 and 100 µM of the (Arg)8 core peptide was also measured.  
The cone-like spot seemed to have been the result of the migration of two different species in the 
sample.  The base of the cone appeared to be migrating towards the anode.  This migration 
pattern was similar to that of VIM-2.  However, the tip of the cone-like shape seemed to have 
remained in the same place where it was originally deposited on the TLC paper.  Hence, it 
appears that a fraction of VIM-2 molecules forms (presumably large) immobile aggregates after 
being exposed to the (Arg)8 peptide, which are incapable of moving towards neither the anode 
nor towards the cathode. 
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Figure 4.10: Paper electrophoresis of VIM-2 in the absence and presence of the (Arg)8 core 
peptide.  Prior to electrophoresis, a TLC paper was soaked in HEPES buffer (50 mM, pH 7.0), 
followed by exposure to nitrocefin (20 µM).  All experiments were conducted with 10 µM VIM-
2 and/or 100 µM of the (Arg)8 core peptide.  Top, VIM-2; bottom, VIM-2 + (Arg)8 core peptide; ⊕, anode; ⊖, cathode.  The locations where the samples were applied to the TLC paper are 
indicated by arrows.  
4.10 Dynamic Light Scattering with VIM-2 and the Cationic Peptides 
Since the previous experiments suggested aggregation between VIM-2 and the cationic peptides, 
dynamic light scattering was performed to determine the size of the aggregates.  HEPES buffer 
(20 mM, pH 7.4) was run as a control in these experiments since it was used for the dilution of 
all samples.  The spectrum of HEPES buffer showed one peak with a diameter of 358 nm (see 
Figure 4.11).  However, this peak represented only 0.1% of the mass of the buffer sample, hence 
rendering this peak negligible.  Therefore, the data was consistent with the buffer not scattering 
in solution.      
⊕ ⊖ 
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Figure 4.11: Dynamic light scattering following the reaction between VIM-2 and the (Arg)8 core 
peptide.  All experiments were conducted in HEPES buffer (20 mM, pH 7.4) at a temperature of 
25 °C.  VIM-2 and the (Arg)8 core peptide were measured at final concentrations of 8 µM and 80 
µM, respectively.  Spectra of HEPES buffer (blue), VIM-2 (green), the (Arg)8 core peptide (red), 
and VIM-2 + (Arg)8 peptide (purple).  The results are presented as particle size distributions. 
The spectrum of a sample containing 8 µM VIM-2 demonstrated two peaks: one exhibited a 
diameter of 5.0 nm while the other peak displayed a diameter of 358 nm (see Figure 4.11).  The 
peak at 358 nm represented only 0.1% of the mass of VIM-2, and was therefore negligible.  The 
peak at 5.0 nm (99.9% of the mass of VIM-2) corresponded to a molecular weight of 28.8 kDa.  
The diameter size of 5.0 nm for VIM-2 is consistent for other MBLs in the same class as VIM-2 
such as NDM-1 (diameter of 4.8 nm; molecular weight of 25 kDa) [133].  Furthermore, similar 
to the dynamic light scattering experiments conducted with NDM-1, a small amount of VIM-2 
(calculated as 0.1% mass by dynamic light scattering instruments) formed non-specific 
aggregates due to the high concentration of protein used in the experiments.  A sample 
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containing 80 µM of the (Arg)8 core peptide revealed two peaks: one with a diameter of 1.2 nm 
and the other exhibiting a diameter of 222 nm (see Figure 4.11).  The peak at 222 nm was 
composed 0.1% of the mass of the (Arg)8 core peptide, and was therefore negligible.  The peak at 
1.2 nm represented 99.9% of the mass of the (Arg)8 core peptide.  The sample containing both 
VIM-2 and the (Arg)8 peptide showed only one peak with a diameter of 668 nm (see Figure 
4.11).  This data is consistent with the formation of large aggregates between VIM-2 and the 
(Arg)8 core peptide since the individual peaks of VIM-2 and the (Arg)8 core peptide were no 
longer visible in the spectrum.  Furthermore, the sample containing both VIM-2 and the (Arg)8 
core peptide showed visual aggregation at the concentrations employed since the sample became 
turbid (see Figure 4.12).              
 
Figure 4.12: Visual aggregation following the reaction of VIM-2 with the (Arg)8 core peptide.  
The experiment was performed in HEPES buffer (20 mM, pH 7.4) at a temperature of 25 °C.  
VIM-2 and the (Arg)8 core peptide were employed at final concentrations of 8 µM and 80 µM, 
respectively.  These are the same concentrations employed in the dynamic light scattering 
studies.  Cuvette with VIM-2 (left), and VIM-2 + (Arg)8 core peptide (right).   
The dynamic light scattering experiments were repeated with increasing inhibitor 
concentrations to determine the amount of inhibitor necessary for the formation of the 
aggregates.  As in the previous experiments, the spectrum of 8 µM VIM-2 demonstrated two 
peaks: one revealing a diameter of 5.0 nm, the other displaying a diameter of 276 nm (see Figure 
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4.13).  Following the addition of the (Arg)8 core peptide to the sample (concentration of 1.6 µM; 
0.2 equivalents), the spectrum exhibited only one peak at a diameter of 219 nm (see Figure 4.13).  
Therefore, these results (surprisingly) suggest that aggregation occurs with only 0.2 molar 
equivalents of inhibitor.  Addition of 0.5, 1, 2, 5 and 10 molar equivalents of inhibitor to the 
sample resulted in the appearance of only one peak at a diameter of 361, 528, 532, 667 and 692 
nm, respectively.  Therefore, a steady increase in the size of the aggregates was observed until it 
reached a plateau at ≥ 5 molar equivalents of inhibitor (see Figure 4.13 inset). 
 
Figure 4.13: Dependence of the aggregate diameter on the concentration of the (Arg)8 core 
peptide.  All experiments were conducted in HEPES buffer (20 mM, pH 7.4) at a temperature of 
25 °C.  VIM-2 was measured at a final concentration of 8 µM.  The (Arg)8 core peptide was 
employed at final concentrations of 1.6, 4, 8, 16, 40 and 80 µM.  Spectra of VIM-2 (blue), VIM-
2 + 1.6 µM (0.2 eq) of the (Arg)8 core peptide (red), VIM-2 + 4 µM (0.5 eq) of the (Arg)8 core 
peptide (green), VIM-2 + 8 µM (1 eq) of the (Arg)8 core peptide (purple), and VIM-2 + 80 µM 
(10 eq) of the (Arg)8 core peptide (pink).  The results are presented as particle size distributions.  
The inset shows the particle size distribution as a function of inhibitor concentration.   
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4.11 Reversibility of VIM-2 Aggregation   
To assess whether VIM-2 aggregation is reversible, sodium sulfate was added to the sample 
containing 8 µM VIM-2 and 80 µM of the (Arg)8 core peptide after the dynamic light scattering 
measurements.  A salt was added since previous studies demonstrated that salts had the ability to 
alleviate inhibition (see Table 4.4).  As shown in Figure 4.14, the addition of Na2SO4 greatly 
diminished the scattering intensity in the absorption spectrum of the sample.  Indeed, the 
Na2SO4-treated VIM-2/(Arg)8 peptide sample displayed a spectrum similar to that of the 
spectrum obtained by addition of the individual spectra of VIM-2 and the (Arg)8 core peptide 
(see Figure 4.14).  Therefore, the results indicate that the aggregation of VIM-2 in the presence 
of the (Arg)8 core peptide is reversible, although a small degree of light scattering could still be 
observed in the spectrum even after the addition of Na2SO4 (see Figure 4.14).  Furthermore, the 
addition of Na2SO4 to the visually aggregated sample containing VIM-2 and the (Arg)8 core 
peptide diminished the turbidity of the sample, resulting in the disappearance of the white 
precipitate (results not shown).  Finally, activity assays were performed on the sample in the 
absence and presence of Na2SO4.  The results demonstrated that VIM-2 regained ~ 30% of its 
original activity upon the addition of Na2SO4 to the aggregated sample.    
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Figure 4.14: Absorption spectra of VIM-2 in the presence of the (Arg)8 core peptide.  Spectra 
were measured in HEPES buffer (50 mM, pH 7.0) at room temperature.  VIM-2, the (Arg)8 core 
peptide and sodium sulfate were employed at final concentrations of 1 µM, 5 µM and 25 mM, 
respectively.  Spectrum of VIM-2 (blue), the (Arg)8 core peptide (red), VIM-2 + (Arg)8 core 
peptide (green), and VIM-2 + (Arg)8 core peptide + sodium sulfate (purple).  The solid lines 
indicate experimental data while the dashed line denotes the additive spectrum obtained by the 
addition of the blue and red traces.  The spectra represent the average of three independent 
experiments. 
Since the UV-Vis spectra suggested that the aggregation between VIM-2 and the cationic 
peptides was reversible, fluorescence studies were performed to further confirm the reversibility 
of this phenomenon.  Previous fluorescence studies demonstrated a high level of scattering at 
295 nm for samples containing both VIM-2 and cationic peptides (see Figure 4.6 and Figure 4.7).  
For the fluorescence studies, a sample containing VIM-2 and the (Arg8Cys)2 core peptide 
(peptide 15) was measured, and was shown to have an elevated level of scattering at 295 nm in 
comparison to that of the additive spectrum (see Figure 4.15).  To determine the reversibility of 
this aggregation, TCEP was added to the sample.  The results revealed that the addition of TCEP 
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significantly reduced the level of scattering at 295 nm.  This result is a consequence of TCEP 
being capable of breaking the disulfide bond of the (Arg8Cys)2 core peptide to yield the 
(Arg)8Cys peptide (peptide 14), which scatters significantly less than the disulfide (see Figure 
4.7).  However, the scattering intensity at 295 nm of the sample containing VIM-2, the 
(Arg8Cys)2 peptide and TCEP remained higher than that of the sample containing VIM-2, the 
(Arg)8Cys peptide and TCEP.  This result may be due to the former sample containing twice as 
many molecules of (Arg)8Cys peptide. Nevertheless, these results imply that the reaction 
between VIM-2 and the cationic peptides was (at least partially) reversible akin to the previous 
results obtained from the UV-Vis experiments.       
 
Figure 4.15: Fluorescence emission spectra of VIM-2 in the presence of the (Arg)8Cys and the 
(Arg8Cys)2 core peptides.  The spectra were measured in HEPES buffer (50 mM, pH 7.0) at 
room temperature using an excitation wavelength of 295 nm.  VIM-2, the cationic peptides and 
TCEP were employed at final concentrations of 1 µM, 5 µM and 25 µM, respectively.  Spectrum 
of VIM-2 + (Arg)8Cys peptide + TCEP (blue), VIM-2 + (Arg8Cys)2 peptide (red), and VIM-2 + 
(Arg8Cys)2 peptide + TCEP (green).  The spectra represent the average of three independent 
experiments. 
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4.12 FRET Studies  
Since previous experiments indicated the occurrence of aggregation between VIM-2 in the 
presence of the cationic peptides, fluorescence resonance energy transfer (FRET) was employed 
to confirm the presence of these protein aggregates.  VIM-2 was labeled with either Alexa Fluor 
488 (donor) or Alexa Fluor 546 (acceptor).  The fluorescence emission spectrum of VIM-2 
labeled with Alexa Fluor 488 in the presence of the (Arg)8Cys core peptide (peptide 14) 
demonstrated one distinct peak at a wavelength of 514 nm (see Figure 4.16).  The fluorescence 
emission spectrum of VIM-2 labeled with Alexa Fluor 546 in the presence of the (Arg)8Cys core 
peptide showed a single peak at a wavelength of 568 nm (see Figure 4.16).  The fluorescence 
emission spectrum for the sample containing both of the labeled portions of VIM-2 exhibited two 
distinct peaks; one at a wavelength of 514 nm and another at a wavelength of 568 nm (see Figure 
4.16).  If there was no interaction between the donor- and acceptor-labeled VIM-2, the 
experimental spectrum should be equal to that of the added spectra of VIM-2 labeled with Alexa 
Fluor 488 and VIM-2 labeled with Alexa Fluor 546.  However, the experimental data revealed 
that there was an interaction between the labeled proteins since the experimental fluorescence 
spectrum demonstrated quenching of the peak at 514 nm, but no change in the peak at 568 nm 
(compare green and purple traces in Figure 4.16).  Therefore, the results indicate that there was 
no FRET between the samples as there was no increase in the λmax of the peak at 568 nm to 
accompany the quenching of the peak at 514 nm.  Furthermore, the distance between the donor 
and acceptor moieties of the labeled proteins was calculated to be ~ 90 Å.  Such a large distance 
between the labeled proteins is indicative of very weak FRET, and, hence, of the absence of 
protein-protein interactions.     
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Figure 4.16: Fluorescence emission spectra of labeled VIM-2.  The spectra were measured in 
HEPES buffer (50 mM, pH 7.2) at room temperature using an excitation wavelength of 492 nm.  
A portion of VIM-2 was labeled with Alexa Fluor 488 (donor) while another portion of VIM-2 
was labeled with Alexa Fluor 546 (acceptor).  Both labeled portions of VIM-2 were both 
employed at a concentration of 100 nM while the (Arg)8Cys core peptide was used at a final 
concentration of 400 nM.  Spectrum of VIM-2 labeled with Alexa Fluor 488 + (Arg)8Cys peptide 
(blue), VIM-2 labeled with Alexa Fluor 546 + (Arg)8Cys peptide (red), VIM-2 labeled with 
Alexa Fluor 488 + VIM-2 labeled with Alexa Fluor 546 + (Arg)8Cys peptide (green and purple).  
The solid lines denote experimental data while the dashed line indicates the additive spectrum 
obtained by the addition of the blue and red traces.  The curves represent the average of three 
independent experiments.   
In light of the absence of protein-protein FRET, it was of interest to gain insight into the 
location of the peptide binding site by FRET.  The fluorescence emission spectrum of the sample 
containing (donor-) labeled VIM-2 demonstrated one distinct peak at a wavelength of 515 nm 
(see Figure 4.17).  Furthermore, the fluorescence emission spectrum of the acceptor-labeled 
(Arg)8Cys core peptide showed one distinct peak at a wavelength of 567 nm (see Figure 4.17).  
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The fluorescence emission spectrum of the sample containing both labeled VIM-2 and the 
labeled (Arg)8Cys peptide demonstrated distinct peaks at 514 nm and 566 nm (see Figure 4.17).   
 
Figure 4.17: Fluorescence emission spectra of labeled VIM-2 and the labeled (Arg)8Cys core 
peptide.  The spectra were measured in HEPES buffer (50 mM, pH 7.2) at room temperature 
using an excitation wavelength of 492 nm.  VIM-2 was labeled with Alexa Fluor 488 while the 
(Arg)8Cys core peptide was labeled with Alexa Fluor 546.  Labeled VIM-2 and the labeled 
(Arg)8Cys core peptide were measured at final concentrations of 200 nM and 800 nM, 
respectively.  Spectra of labeled VIM-2 (blue), the labeled (Arg)8Cys core peptide (red), and 
labeled VIM-2 + labeled (Arg)8Cys peptide (green and purple).  The solid lines indicate 
experimental data while the dashed line denotes the additive spectrum obtained by the addition 
of the blue and red traces.  The curves represent the average of three independent experiments.  
If there was no interaction between the labeled protein and the labeled peptide, the 
experimental spectrum should correspond to the sum of labeled VIM-2 and labeled (Arg)8Cys 
peptide.  However, actual experimental data demonstrated that there was an interaction between 
the labeled protein and the labeled peptide since the experimental emission spectrum 
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demonstrated significant quenching of the peak at 514 nm, but no change in peak in intensity at 
568 nm in comparison to the additive spectrum (see Figure 4.17).  When the distance between 
the labeled protein and labeled peptide was calculated, a very large distance of ~ 70 Å was 
obtained.       
Since significant FRET was not observed between labeled VIM-2 and the labeled (Arg)8Cys 
core peptide, additional studies were conducted to reveal the underlying cause of this 
phenomenon.  Hence, activity assays were performed to determine the inhibitory potency of the 
labeled peptides.  The results revealed that the labeled peptides were essentially non-inhibitory.  
For instance, exposure of VIM-2 to 5 µM donor- or acceptor-labeled (Arg)8Cys resulted in only 
5% inhibition, an observation very different from that noted with the unlabeled peptide for which 
an IC50 value of 118 nM was noted (see Table 4.1).  Furthermore, fluorescence studies were 
conducted to determine if, in the presence of VIM-2, the labeled peptides demonstrated high 
levels of scattering at 295 nm.  The results revealed that the levels of scattering at 295 nm for the 
labeled peptides in the presence of VIM-2 were much lower than those obtained with their 
unlabeled equivalents, and essentially identical to those of the additive spectra (see Figure 4.18).  
This observation suggests that no aggregation occurred between VIM-2 and the (Arg)8 peptide 
due to the label on the peptide.  Therefore, it is also likely that the dye molecule prevented the 
peptide from binding VIM-2, which could explain the absence of FRET in the previous 
experiments.     
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Figure 4.18: Fluorescence emission at 295 nm of VIM-2 and the (Arg)8Cys core peptide in the 
absence and the presence of fluorescent labels.  The fluorescence emission spectra were 
measured in HEPES buffer (50 mM, pH 7.2) at room temperature using an excitation wavelength 
of 492 nm.  Columns of unlabeled species (VIM-2 or peptide) (blue), the (Arg)8Cys core peptide 
labeled with Alexa Fluor 488 (orange), and the (Arg)8Cys core peptide labeled with Alexa Fluor 
546 (pink).  The VIM-2 + (Arg)8Cys peptide (additive) data was obtained by the addition of the 
individual VIM-2 and (Arg)8Cys peptide data.  The columns represent the average (± 1 s.d.) of 
three independent experiments.   
4.13 Interaction of Cationic Peptides with IMP-1 
Since cationic peptides were shown to be potent inhibitors of VIM-2, it was of interest to observe 
whether these peptides proved to be effective inhibitors against other metallo-β-lactamases such 
as IMP-1.  The interaction between IMP-1 and the cationic peptides was investigated by 
recording the catalytic activity of IMP-1 in the presence of these peptide inhibitors.  Since 
previous results obtained with VIM-2 suggested that inhibition was dependent on the number of 
arginine residues, peptides containing a varying numbers of core arginine residues were 
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employed as inhibitors of IMP-1.  The results demonstrated that the elongation of the (Arg)5 core 
to an (Arg)8 core peptide had a minimal effect on the inhibitory potency of the peptides with IC50 
values located in the high micromolar range (see peptides 7 and 4 in Table 4.7).  Replacement of 
the N-terminal glycine residue of peptide 4 with a cysteine residue (peptide 14) led to a 
considerable increase in the inhibitory potency with the IC50 value decreasing from over 200 µM 
to 46 µM (compare peptides 4 and 14 in Table 4.7).        
Table 4.7: Inhibition of IMP-1 by various cationic peptides.  Inhibition was assessed at room 
temperature by pre-incubating 2 nM IMP-1 with the desired peptide for 1 min prior to the 
determination of the protein’s catalytic activity following the introduction of 100 µM of 
nitrocefin.  The values represent the mean (± 1 s.d.) of three independent experiments.  The IC50 
values for VIM-2 were taken from Table 4.1.     
Peptide 
IC50 (µM) 
IMP-1 VIM-2 
7 Ac-Gly-Tyr-βAla-(Arg)5-Val-Leu-Arg-OH > 500 > 500 
4 Ac-Gly-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH > 200 0.18 ± 0.01 
14 Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 46 ± 4 0.118 ± 0.021 
15 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
             │ 
Ac-Cys-Tyr-βAla-(Arg)8-Val-Leu-Arg-OH 
122 ± 13 0.013 ± 0.001 
11 Poly-arginine (5 to 15 kDa)  0.72 ± 0.06  0.017 ± 0.004 
The cysteine-containing (Arg)8 core peptide was dimerized to give the disulfide-containing 
analogue (peptide 15).  This peptide was shown to be a less potent inhibitor of IMP-1 with an 
IC50 value of 122 ± 13 µM, a finding quite distinct from that documented for VIM-2 (see Table 
4.1).  Furthermore, the results revealed that poly-arginine was the only potent inhibitor of IMP-1 
with an IC50 value of 720 ± 60 nM (see peptide 11 in Table 4.7).  This data suggested that the 
cationic peptides are generally less potent inhibitors of IMP-1 in comparison to VIM-2. 
Since previous studies with VIM-2 suggested aggregation of the protein in the presence of the 
cationic peptides, fluorescence studies were conducted with IMP-1 to determine whether this 
aggregation was also occurring between IMP-1 and the cationic peptides.  In the previous 
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studies, a high fluorescence intensity at 295 nm was indicative of aggregation in the samples.  As 
shown in Figure 4.19, the fluorescence emission spectrum of IMP-1 demonstrated one distinct 
peak at a wavelength of 334 nm.  In the presence of poly-arginine, the fluorescence spectrum of 
IMP-1 exhibited significant quenching, but no shift of λmax.  Furthermore, similar to the results 
obtained with VIM-2, a considerable increase in fluorescence intensity at 295 nm was detected 
for the sample containing IMP-1 and poly-arginine.  Although such increase in fluorescence 
intensity was lower than that of the VIM-2 samples, these results suggest aggregation of the 
protein in the presence of poly-arginine. 
 
Figure 4.19: Fluorescence emission spectra of IMP-1 with poly-arginine.  The spectra were 
measured in HEPES buffer (50 mM, pH 7.2) at room temperature using an excitation wavelength 
of 295 nm.  IMP-1 and poly-arginine were employed at final concentrations of 1 µM and 5 µM, 
respectively.  Spectrum of IMP-1 (black), poly-arginine (blue) and IMP-1 + poly-arginine (red 
and green).  The solid lines represent experimental data while the dashed line indicates the 
additive spectrum obtained by the addition of the black and blue curves.  The spectra represent 
the average of three independent experiments.   
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As in the case of VIM-2, the difference in fluorescence intensity of IMP-1 at 295 nm between 
the experimental spectrum and the additive spectrum was evaluated for a variety of cationic 
peptides.  The results revealed that the difference in fluorescence intensity at 295 nm (and hence 
the degree of scattering) increased with the number of (core) arginine residues (see Figure 4.20), 
a finding identical to those obtained with VIM-2 (see Figure 4.7).  Furthermore, the ΔFI values 
obtained with IMP-1 correlate with the inhibitory potency of the peptides (just as it did for VIM-
2), except for the (Arg8Cys)2 peptide which shows a higher ΔFI value, but lower inhibitory 
potency than its reduced (Arg)8Cys analogue (see Table 4.7).  Therefore, IMP-1 and VIM-2 
exhibited a similar dependence on the number of core arginine residues for inhibition and 
fluorescence intensity.  However, in comparison to VIM-2, the cationic peptides appear to be 
less inhibitory against IMP-1.   
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Figure 4.20: Difference in fluorescence intensity at 295 nm for the emission spectra of IMP-1 
with various cationic peptides.  The spectra were measured in HEPES buffer (50 mM, pH 7.2) at 
room temperature using an excitation wavelength of 295 nm.  IMP-1 and the cationic peptides 
were employed at final concentrations of 1 µM and 5 µM, respectively.  The purple squares 
correspond to the peptides that contained a cysteine residue in their N-terminus instead of a 
glycine residue (peptides 14 and 15).  The 16 arginine core peptide denotes the (Arg8Cys)2 
peptide (peptide 15) while the >28 core peptide represents poly-arginine (peptide 11).  
∆Fluorescence intensity denotes the difference in fluorescence intensity between the 
experimental and additive spectra.  Data shown represent the average of three independent 
experiments.  The error bars symbolize the mean (± 1 s.d.) of the three independent experiments.   
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Chapter 5: Discussion 
The discovery of antibiotics over 70 years ago was expected to bring about an end to infectious 
diseases [134].  However, despite the progress in the design of antibiotics, their golden age is 
rapidly coming to an end in the midst of an increasing emergence of infectious diseases, more 
specifically bacterial infections [4, 135].  While β-lactam antibiotics (i.e., penicillins, 
cephalosporins and carbapenems) remain the most widely used antibacterial agents, their 
effectiveness against bacterial infections is quickly decreasing due to the growing number of 
bacteria possessing antibiotic resistance mechanisms [90, 135].  The most prevalent manner by 
which bacteria become resistant to β-lactams is through the production of enzymes termed β-
lactamases which are capable of hydrolyzing these antibiotics [90, 91, 135].  Among the 
different classes of β-lactamases, class B enzymes (termed metallo-β-lactamases, MBLs) rely on 
the presence of zinc ions for their catalytic function [92].  MBLs are rapidly becoming a global 
concern since they not only possess the capacity to cleave most classes of β-lactam antibiotics, 
but they are also able to hydrolyze class A β-lactamase inhibitors (i.e., clavulanic acid) as well as 
carbapenems, antibiotics with the broadest spectrum of activity rendering them the last resort 
antibiotics for many serious bacterial infections [92, 93, 96, 98, 116].  Even with the decreasing 
number of treatment options presently available, there are no clinically approved inhibitors for 
MBLs [136].  Therefore, new options must be pursued in order to find inhibitors for these 
increasingly problematic enzymes.    
5.1 Cationic Peptide Inhibitors 
Cationic peptides have received considerable attention as potential inhibitors of MBLs since 
preliminary studies (unpublished) demonstrated that S-pNA, a lethal factor (LF) substrate 
containing an octa-arginine motif, had the ability to inhibit MBLs.  However, the structure-
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activity relationship between the MBLs and S-pNA still remains unknown.  Henceforth, the 
majority of the cationic peptides used in this study originated around modifications of the amino 
acid sequence of S-pNA to allow for a more thorough study of the structure-activity relationship 
between MBLs and cationic peptides.  Initially, in the case of alterations to the C-terminal region 
of S-pNA, whether it was a substitution of the C-terminal moiety or of C-terminal amino acid 
residues, only minor changes in the inhibitory potency of the peptides were observed (see Table 
4.1).  Even incorporation of a zinc-binding C-terminal hydroxamate moiety into the peptide was 
found to have a negligible effect on the inhibition of VIM-2.  This feature is quite different from 
that noted with the zinc endopeptidase LF, where the hydroxamate moiety was found to be a 
strong zinc-binding group [137].  Thus, these observations are most likely a consequence of the 
C-terminal end of the peptide not having the ability to interact with VIM-2’s active site.  
Therefore, it appears that the C-terminal end of the cationic peptides plays a minimal role in the 
inhibition of the MBLs. 
The structure of S-pNA was modified to create cationic peptides varying in their number of 
core arginine residues.  As a result of this modification, a significant decrease in the inhibitory 
potency of the peptides was detected upon the shortening of the octa-arginine core to a tetra-
arginine core.  Hence, the most potent inhibitors of VIM-2 were poly-arginine and the 
(Arg8Cys)2 core peptide (peptides 11 and 15 in Table 4.1, respectively).  This observation may 
be a consequence of the increasing number of arginine residues having the capacity to bind 
additional negatively charged regions on the surface of VIM-2.  Furthermore, the results revealed 
that the (Arg)6 core peptide was a considerably more potent inhibitor of VIM-2 than the (Arg)5 
core peptide (by a factor of 200).  Thus, the additional (sixth) core arginine residue may have the 
ability to bind an additional negatively charged site on the surface of VIM-2.  These observations 
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gained further support through the comparison of the inhibitory potency of the reduced and 
oxidized forms of the (Arg)8Cys peptide.  The oxidized form of this peptide was the most potent 
inhibitor of VIM-2, although its two octa-arginine motifs are separated by six other non-
positively charged amino acid residues.  These observations support the notion that the positively 
charged arginine residues of the cationic peptides may bind negatively charged regions on the 
surface of VIM-2.  Therefore, it appears that the number of arginine residues in the peptidic 
chain is important for the inhibition of VIM-2 by the cationic peptides. 
The importance of arginine residues for the inhibition of VIM-2 was also evaluated through 
the incorporation of a tetra-lysine core peptide, which was found to be a poor inhibitor of VIM-2.  
However, upon the replacement of the C-terminal proline and the (Lys)4 motif of this peptide 
with arginine residues, a significant increase in inhibitory potency was observed, underlining the 
importance of arginine residues for the effective inhibition of VIM-2.  Although arginine and 
lysine residues are both positively charged at neutral pH, the difference in their inhibitory 
potencies may be a consequence of the nitrogen atoms of the guanidinium group allowing for 
interactions in three possible directions (whereas the functional group of lysine only allows for 
one such direction) [138].  Furthermore, the Ac-Nle-(Arg)4-Val-Leu-Arg-OH peptide was found 
to be a significantly more potent inhibitor than Ac-Gly-Tyr-βAla-(Arg)4-Val-Leu-Arg-OH (see 
Table 4.1).  Hence, minor differences in the N-terminal residues of both of these peptides (Ac-
Nle vs. Ac-Gly-Tyr-βAla) caused a significant alteration in their inhibitory potencies.  These 
observations may be a consequence of the N-terminal end of the cationic peptide having the 
ability to (strongly) bind to VIM-2.  This notion gained further support upon the substitution of 
the N-terminal glycine residue in the amino acid sequence of S-pNA with an N-terminal cysteine 
residue, revealing that the (Arg)4Cys and the (Arg)8Cys core peptides were more potent 
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inhibitors of VIM-2 than their glycine-containing equivalents (see Table 4.1).  These 
observations may be a consequence of the cysteine residue’s sulfhydryl group interacting with 
the protein (possibly interacting with a zinc ion in the active site of VIM-2) [139].  Interestingly, 
these peptides remain potent inhibitors of VIM-2 in their oxidized state, although their sulfhydryl 
groups are forming disulfide bridges.  The increased inhibitory potency of the oxidized peptides 
might be a consequence of having twice as many core arginine residues.  Therefore, it is most 
likely a combination of the number of core arginine residues in conjunction with the N-terminal 
region (Ac-Nle vs. Ac-Gly-Tyr-βAla) of the cationic peptides which are important for their 
inhibitory effect on VIM-2.     
To further investigate the structure-activity relationship between MBLs and cationic peptides, 
various β-lactam substrates other than nitrocefin including a variety of cephalosporins, 
benzylpenicillin and imipenem were employed in the assessment of the inhibitory potency of S-
pNA.  The results demonstrated that nitrocefin and the nitrocefin-like substrates (UW-57 and 
UW-58) were the substrates with which the highest degree of inhibition by S-pNA was observed, 
and that the inhibitory potency of S-pNA decreased significantly upon the substitution of 
nitrocefin with other substrates.  In particular, inhibition was found to be susceptible to changes 
in the R2 moiety of cephalosporins.  Furthermore, in view of the ionic nature of the cationic 
peptides, the effect of salts on VIM-2 inhibition was studied, revealing that all salts, especially 
those containing divalent anions, were capable of relieving S-pNA-mediated inhibition of VIM-
2.  It is not unlikely that the anions of the salts bind to the positively charged arginine residues of 
the peptides, thus decreasing their inhibitory potency against VIM-2.  
 
 
 
 
100 
 
5.2 Mechanism of Inhibition 
The mode of inhibition of VIM-2 by S-pNA was found to be complex.  The data obtained during 
the study of the inhibition of VIM-2 by S-pNA was fit to two mechanisms involving (a) an 
enzyme-product-inhibitor ternary complex, and (b) hyperbolic (partial) mixed-type inhibition 
which cannot be distinguished experimentally by steady-state kinetic assays.     
Since the enzyme kinetics of the reaction between VIM-2 and S-pNA could be fit to two 
indistinguishable mechanisms, stopped-flow spectrophotometry was used to differentiate 
between both mechanisms.  Single-turnover experiments were conducted using poly-arginine as 
an inhibitor.  As expected, the results demonstrated the presence of the nitrocefin peak at 390 nm 
and a peak at 490 nm indicative of the presence of hydrolyzed nitrocefin.  However, there was no 
evidence of a peak at 665 nm.  Previous experiments focusing on CcrA and NDM-1 
demonstrated a peak at 665 nm [132, 140], which corresponds to a ring-opened anionic nitrogen 
intermediate of nitrocefin [132].  Although, there was no evidence of this peak in the studies 
performed on VIM-2, the intermediate was also absent in experiments conducted on MBLs such 
as BcII, Bla2 and IMP-1 [141–143].  Therefore, it is not unusual that the stopped-flow 
experiments performed with VIM-2 did not demonstrate any evidence of the nitrocefin 
intermediate since the occurrence of this species seems to depend on the MBL employed.  Two 
possible scenarios could account for the absence of the intermediate in the mechanism of VIM-2-
mediated nitrocefin hydrolysis: (i) the intermediate is not formed, and (ii) the intermediate forms, 
but decays so rapidly (within less than 1 ms) that stopped-flow instruments are unable to detect 
it.  Regardless of the presence or absence of this intermediate, the stopped-flow studies could 
still help distinguish between the two mechanisms that could be used to describe the interaction 
between VIM-2 and cationic peptides.  Following the addition of nitrocefin (pre-exposed to poly-
 
 
101 
 
arginine) to VIM-2, the emergence of the peak at 490 nm (hydrolyzed nitrocefin) was 
significantly delayed.  Furthermore, evidence of light scattering in the spectrum became more 
apparent as the reaction progressed.  These observations demonstrate that the hydrolysis of 
nitrocefin is strongly inhibited, a finding to be expected in view of poly-arginine’s high 
inhibitory potency.  This strong inhibition also persisted when poly-arginine was pre-exposed to 
VIM-2 prior to the addition of nitrocefin.  However, the absorbance of both nitrocefin and 
hydrolyzed nitrocefin were considerably higher than those revealed with nitrocefin pre-exposed 
to poly-arginine due to light scattering.  Nonetheless, it was observed that, regardless of whether 
poly-arginine was pre-exposed to VIM-2 or to nitrocefin, the A390 and A490 curves demonstrated 
similar rates of nitrocefin hydrolysis suggesting that inhibition precedes protein aggregation.  
Furthermore, the inhibition of VIM-2 by poly-arginine appears to follow the hyperbolic (partial) 
mixed-type inhibition.  This is apparent since the first turnover of nitrocefin in this mechanism 
would be slow (i.e., inhibited) due to the pre-product stage inhibition through the production of 
the EIS complex [129].  If the mechanism involving the enzyme-product-inhibitor ternary 
complex was followed, the first turnover of nitrocefin would have been more rapid since the 
inhibitor has a higher affinity for the EP complex than for the free enzyme [128], a feature not 
observed in the experiments.  Therefore, the inhibition of VIM-2 by poly-arginine most likely 
follows the hyperbolic (partial) mixed-type inhibition. 
Double-turnover stopped-flow experiments were also performed to distinguish the two 
mechanisms of inhibition [hyperbolic (partial) mixed-type inhibition vs. enzyme-product-
inhibitor ternary complex].  Single-wavelength stopped-flow analyses for the substrate peak at 
390 nm and product peak at 490 nm demonstrated that in the presence of the (Arg)7 core peptide, 
the rate of nitrocefin hydrolysis only slightly decreased during the first turnover.  However, the 
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rate reduction became increasingly prominent during the second turnover.  The data appears to 
suggest that the mechanism producing the enzyme-product-inhibitor ternary complex (since the 
first turnover was rapid).  Therefore, when the results from both the single and double-turnover 
experiments are taken into consideration, it seems not unlikely that the inhibition of VIM-2 by 
the cationic peptides follows a combination of both of the mechanisms of inhibition.  Such 
combination would still allow for the production of the EIS complex.  However, the EIS 
complex would still be active allowing the turnover of substrate for the formation of product 
resulting in the formation of an EPI complex as per the mechanism involving the enzyme-
product-inhibitor ternary complex (see Figure 5.1).  It is important to note that the possibility of 
the mechanism of VIM-2 inhibition being slightly different for poly-arginine and the (Arg)7 
peptide cannot be ruled out at the present time.   
 
Figure 5.1: Proposed scheme for the inhibition of VIM-2 by cationic peptides. 
5.3 Protein Aggregation 
Intrinsic tryptophan fluorescence studies were conducted to further investigate the structure-
activity relationship between the MBLs and the cationic peptides.  These studies demonstrated 
that the interaction between VIM-2 and the cationic peptides only induced minimal 
conformational changes within the protein since only slight alterations of the fluorescence 
emission spectra of VIM-2 (shift in λmax or change in fluorescence intensity) were observable 
E + S ES EP
EISEI + S
 + +
I I
KM kcat
Ki αKi
EPI
βkcatαKM
 +
I
E + P
E + P + I
 
 
103 
 
upon the addition of a cationic peptide.  However, the fluorescence emission spectra of VIM-2 
displayed a dramatic increase in fluorescence intensity at 295 nm upon the addition of cationic 
peptides with greater than six arginine core residues.  This prominent increase in fluorescence 
intensity is indicative of light scattering caused by protein aggregation.  Furthermore, the degree 
of scattering increased with the number of arginine residues in the peptides, an observation 
corresponding well with the increase in their inhibitory potency.  In addition, UV-Vis 
spectroscopy revealed an increase in absorbance in the short wavelength limb (especially 
prominent at 250 nm) of the VIM-2 spectrum upon the addition of the cationic peptides, 
suggesting protein aggregation. 
To estimate the size of the aggregates, native PAGE was performed.  This study demonstrated 
the presence of an interaction between VIM-2 and the cationic peptides since the VIM-2 band on 
the gel diminished in intensity upon the addition of the cationic peptides.  However, no 
aggregates of higher molecular weight could be detected to justify the decreased intensity of the 
VIM-2 bands, or to confirm the presence of distinct aggregates in the samples.  Paper 
electrophoresis confirmed the absence of a charge reversal (from negative to positive) upon the 
addition of a cationic peptide to VIM-2.  Indeed, two distinct migration patterns were observed 
on the TLC paper with one remaining stationary, and the other migrating, as expected, towards 
the anode.  The sample that remained stationary during the paper electrophoresis is most likely 
due to the aggregates being too large to migrate within the electric field, a hypothesis gaining 
support from the inability to detect aggregates of higher molecular weights during native PAGE.  
Therefore, it appears that large aggregates are formed during the interaction between VIM-2 and 
the more potent cationic peptide inhibitors.  
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Since the size of aggregates formed between VIM-2 and the cationic peptides could not be 
determined by native PAGE, dynamic light scattering experiments were performed to estimate 
the size of the aggregates.  As a control, VIM-2 was analyzed, demonstrating an average 
diameter of 5.0 nm.  This diameter is similar to that obtained for NDM-1, which is in the same 
subclass as VIM-2, and was found to have a diameter of 4.8 nm [133].  Upon the addition of the 
(Arg)8 core peptide to VIM-2, an aggregate formed with a diameter of ~ 670 nm.  These 
observations confirm the results from the native PAGE studies that only one large aggregate is 
formed during the interaction between VIM-2 and the cationic peptides.  Indeed, the sample 
demonstrated visible aggregation (precipitate; increased turbidity), which may be a consequence 
of the high concentrations employed for VIM-2 and the cationic peptide.  Furthermore, the 
dynamic light scattering experiments were also conducted with increasing concentrations of the 
cationic peptide to determine the equivalent amount of inhibitor necessary for the formation of 
aggregates.  Even at only 0.2 molar equivalents of inhibitor, aggregation was detected in the 
sample.  In addition, the size of the aggregates increased with the concentration of inhibitor.  
These observations suggest that only a small quantity of peptide is required to induce the 
formation of VIM-2 aggregates, and that the aggregates grow in size at higher concentrations of 
inhibitor. 
UV-Vis spectroscopy was performed to determine the reversibility of the interaction between 
VIM-2 and the cationic peptides.  A salt shown to relieve cationic peptide-mediated inhibition 
was added to the (Arg)8 core peptide-supplemented VIM-2 sample to determine if the 
aggregation was reversible.  The results showed that the addition of Na2SO4 led to a decrease in 
absorbance in the spectrum of the aggregated sample, and a reduction of turbidity.  However, the 
absorbance spectrum of the sample still showed evidence of light scattering following the 
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addition of Na2SO4, suggesting that aggregation is only partially reversible.  This notion was 
further supported through activity assays following the addition of Na2SO4 to the aggregated 
sample.  The results demonstrated that only ~ 30% of VIM-2 activity is recovered following the 
supplementation with Na2SO4.  These observations may be a consequence of VIM-2 misfolding 
during aggregation.  The partial relief of protein aggregation was also confirmed through 
intrinsic tryptophan fluorescence studies.  These investigations demonstrated that TCEP was 
capable of relieving the (Arg8Cys)2 core peptide (peptide 15 in Table 4.1)-mediated aggregation 
of VIM-2 as evidenced by a decrease in the fluorescence intensity at 295 nm.  However, the 
fluorescence intensity of this sample was still considerably higher than that of VIM-2 
supplemented with the reduced (Arg)8Cys peptide (peptide 14 in Table 4.1) suggesting that the 
interaction between VIM-2 and the cationic peptides is only partially reversible. 
5.4 FRET 
FRET studies were conducted to further support the presence of aggregation, and to gain insight 
into the molecular nature of the aggregates.  These studies demonstrated that no FRET was 
observable between donor- and acceptor-labeled VIM-2.  Although FRET was not observable 
between the labeled proteins, these studies showed that there was a quenching of the 
fluorescence intensity of the donor.  These observations may be a consequence of the unlabeled 
peptide interacting with the dye molecule bound to VIM-2, and changing the polarity of the 
micro-environment of the dye.  Furthermore, it is highly unlikely that the absence of FRET was 
caused by improperly labeled reagents since additional tests (e.g., by UV-Vis, PAR assays and 
calculations of the degree of labeling) were conducted to ensure that both of the proteins were 
properly labeled.  Therefore, it is most likely that protein aggregation did not occur with labeled 
VIM-2, and could hence not be detected by FRET. 
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FRET was employed to investigate the binding site of the cationic peptides to VIM-2 since 
activity assays, tryptophan fluorescence and UV-Vis studies, native PAGE, and dynamic light 
scattering investigations all confirmed the presence of an interaction between the MBLs and the 
cationic peptides.  These studies demonstrated that FRET was not observable between the donor-
labeled VIM-2 and the acceptor-labeled (Arg)8Cys peptide, although a quenching of the 
fluorescence intensity of the donor was noticeable.  Additional studies demonstrated that the 
covalent binding of the dye to the (Arg)8Cys peptide caused the peptide to become a 
considerably less potent inhibitor of VIM-2, and prevented aggregation between the unlabeled 
protein and the labeled peptide.  Therefore, it is likely that the labeled peptide is incapable of 
binding to VIM-2, which may account for the absence of FRET during the studies. 
5.5 Inhibition of IMP-1 by Cationic Peptides  
Previous studies revealed that cationic peptides were potent inhibitors of VIM-2.  To investigate 
this further, additional activity assays and tryptophan fluorescence studies were employed to 
determine whether the cationic peptides showed the same inhibitory potency against IMP-1, 
another B1 metallo-β-lactamase.  The cationic peptides proved to be significantly less potent 
against IMP-1 than VIM-2, although the inhibition of both MBLs by the cationic peptides 
appeared to demonstrate the same dependence on the nature of the N-terminal amino acids (Cys 
vs. Gly), and the number of core arginine residues in the peptides.  These observations may be a 
consequence of differences in the electrostatic potentials of VIM-2 and IMP-1 in the regions 
surrounding the active site of both of these MBLs since this is a plausible binding site of the 
cationic peptides.   
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Figure 5.2: Surface of VIM-2 and IMP-1 in terms of their electrostatic potentials.  The amino 
acid residues of interest surrounding the potential cationic peptide binding site are labeled 
according to the BBL numbering scheme.  A plausible cationic peptide binding site is encircled 
in black.  Surfaces of VIM-2 (left) and IMP-1 (right).   
A comparison of the surfaces of VIM-2 and IMP-1 shows that a considerable portion of the 
electrostatic potentials of these two proteins remained similar regardless of some aspartate and 
glutamate substitutions since these regions still possess an overall negative charge (see Figure 
5.2).  However, IMP-1 contains some additional positively charged regions near its active site in 
comparison to that of VIM-2.  These additional positively charged regions stem from Lys224 
and Lys151 which are substituted with an asparagine residue and a tyrosine residue, respectively, 
in the amino acid sequence of VIM-2 (see Figure 5.2).  Furthermore, these lysine residues reside 
in the plausible binding site of the cationic peptides (see Figure 5.2).  If the additional positively 
charged regions in IMP-1 are located in the binding site of the cationic peptides, they may lead to 
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a repulsion of the positively charged arginine core of the cationic peptides.  Therefore, this 
repulsion would render the cationic peptides less inhibitory against IMP-1 since they can no 
longer properly bind to the MBL.  As a consequence, additional core arginine residues may be 
required to span the binding pocket of IMP-1, while avoiding the repulsion of the additional 
lysine residues.  This hypothesis gains support from the observation that poly-arginine and the 
(Arg8Cys)2 peptide remain the most potent inhibitors of IMP-1.  This notion is further supported 
by the observation that the scattering at 295 nm in intrinsic tryptophan fluorescence studies 
performed on IMP-1 was also dependent on the number of arginine residues in the peptides.  
Hence, it appears that the inhibitory potency of the cationic peptides depends on the surface 
characteristics of the MBL under investigation. 
A plausible mechanism for the inhibition of the MBLs by the cationic peptides begins with 
the docking of the cationic peptide to the MBL, resulting in inhibition.  The peptide (by virtue of 
its high positive charge) can then attract other MBL molecules, or change the surface of the 
MBL to promote the formation of aggregates.  Salts are able to relieve MBL inhibition (and 
aggregation) by the cationic peptides since they most likely interact with the peptides rendering 
them incapable of remaining bound to the protein.  
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Chapter 6: Conclusions and Future Studies 
Louis Pasteur once said that microbes always have the last word [144].  With the ever growing 
number of bacteria equipped with antibiotic resistance mechanisms such as target site alterations, 
multidrug efflux pumps and antibiotic-degrading enzymes, bacteria have become highly resilient 
to antibiotics.  It is therefore important that alternatives to antibiotics be developed to help treat 
infectious diseases caused by bacteria which are resistant to almost all known antibiotics.   
This research project explored the possibility of inhibiting MBLs with cationic peptides.  The 
results obtained from this research confirmed that cationic peptides have the ability to inhibit 
VIM-2 and IMP-1.  Furthermore, the inhibitory potency of the cationic peptides was dependent 
on the MBL employed, and the number of core arginine residues in these peptides (IC50 of ~ 10 
nM for the best inhibitor).  In addition, inhibition also depended on the nature of the N-terminal 
residues of the peptides.  Therefore, the peptides containing either an N-terminal cysteine or 
greater than seven core arginine residues demonstrated the highest degree of MBL inhibition.  
The inhibitory potency of the peptides also varied depending on the substrate employed and 
whether or not salt was present in the samples.  Hence, the cationic peptides were more potent 
inhibitors upon the employment of nitrocefin and nitrocefin-like substrates while salts, especially 
those with divalent anions, were shown to relieve this inhibition.  The reaction between the 
MBLs and the cationic peptides also suggested the formation of protein aggregates.  This protein 
aggregation can only occur once the peptide binds and inhibits the MBL.  Furthermore, protein 
aggregation increases with the number of arginine residues in the cationic peptides, and can be 
relieved upon the addition of salt.   
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The mode of inhibition of the MBLs by the cationic peptides is complex, and appears to 
involve the production of an enzyme-product-inhibitor complex and enzyme-substrate-inhibitor 
complex.     
Future studies could include using different enzymes, other than VIM-2 and IMP-1, to 
investigate whether these MBLs are also inhibited by cationic peptides.  Furthermore, different 
peptides varying in their N-terminal residues should be used to further explore the effect of the 
N-terminal moiety on MBL inhibition.  In addition, core arginine residues could be substituted 
with non-positively charged amino acids to see which arginine residues are important for the 
inhibition of the MBLs.  The appropriate rate equation for the observed mechanism of inhibition, 
based on a combination of the mechanism producing an enzyme-product-inhibitor ternary 
complex and hyperbolic (partial) mixed-type inhibition, could to be developed using the King-
Altman method to obtain reliable estimates of the kinetic constants.  Molecular modeling could 
also be used to determine the binding site of the cationic peptides to the MBLs.  Ultimately, if 
the cationic peptides prove to be potent inhibitors of a variety of MBLs, peptidomimetics could 
be used to create novel inhibitors of MBLs.  However, until such time as inhibitors of MBLs are 
developed and clinically approved, education and restraint on the proper use of antibiotics is the 
key to controlling the spread of bacterial antibiotic resistance.  
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